




The National High Blood Pressure Education Program is coordinated by the National Heart, Lung, and Blood Institute; National Institutes of Health; Public Health Service; U.S. Department of Health and Human Services.

THE FIFTH REPORT OF THE JOINT NATIONAL COMMITTEE ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD PRESSURE



National High Blood Pressure Education Program

NATIONAL INSTITUTES OF HEALTH

National Heart, Lung, and Blood Institute

NIH Publication No. 93-1088

January 1993

TABLE OF CONTENTS

FOREWORD	vii	♦
MEMBERS OF THE JOINT NATIONAL COMMITTEE	ix	♦
THE NHBPEP COORDINATING COMMITTEE	xiv	♦
CHAPTER I: INTRODUCTION	1	♦
CHAPTER II: CLINICAL EVALUATION AND PUBLIC HEALTH ASPECTS OF HIGH BLOOD PRESSURE	3	♦
New Classification of High Blood Pressure	3	♦
Detection and Confirmation	4	♦
Measurement	4	
Confirmation and Followup	5	♦
Home Measurement and Ambulatory Automatic Monitoring of Blood Pressure	5	♦
Evaluation	6	
Medical History	7	♦
Physical Examination	7	♦
Laboratory Tests and Diagnostic Procedures	8	♦
Primary Prevention of High Blood Pressure	8	
Community Programs for Blood Pressure Control	9	♦
Cost of Care	10	♦
CHAPTER III: TREATMENT	11	♦
Goal	11	
Lifestyle Modification	11	♦
Tobacco Avoidance	11	♦
Weight Reduction	12	
Moderation of Alcohol Intake	12	♦
Physical Activity	12	
Moderation of Dietary Sodium	13	♦
Potassium	13	
Calcium	13	♦
Magnesium	14	♦
Other Dietary Factors	14	
Relaxation and Biofeedback	14	♦
Summary	14	
Pharmacologic Treatment	15	♦
Efficacy	15	♦
Stage 1 and Stage 2 Hypertension	15	
Initial Drug Therapy	15	♦
Special Considerations	16	
Dosage and Followup	17	♦

♦	Stage 3 and Stage 4 Hypertension	23
♦	Isolated Systolic Hypertension	23
♦	Step-Down Therapy	23
♦	J-Curve Hypothesis	26
♦	Resistant Hypertension	26
♦	Hypertensive Crises: Emergencies and Urgencies	27
♦	Long-Term Adherence to Therapy	27
♦	Followup Visits	27
♦	Planned Patient Education Programs	29
♦	Strategies To Improve Adherence to Therapy and Control of High Blood Pressure	29
♦	CHAPTER IV: SPECIAL POPULATIONS AND SITUATIONS	31
♦	Hypertension in African Americans and Other Racial and Ethnic Minorities	31
♦	Hypertension in Children	31
♦	Hypertension in Women	33
♦	Hypertension Associated With Oral Contraceptives	33
♦	Hypertension in Pregnancy	34
♦	Estrogen Replacement Therapy and Blood Pressure	35
♦	Hypertension in Older Patients	35
♦	Patients With Hypertension and Coexisting Cardiovascular Diseases	37
♦	Patients With Cerebrovascular Disease	37
♦	Patients With Coronary Artery Disease	37
♦	Patients With Cardiac Failure	37
♦	Patients With Left Ventricular Hypertrophy	38
♦	Patients With Peripheral Vascular Diseases	38
♦	Patients With Hypertension and Other Coexisting Diseases	38
♦	Patients With Renal Disease	38
♦	Patients With Diabetes Mellitus	39
♦	Patients With Dyslipidemia	39
♦	Patients With Chronic Airways Disease or Bronchial Asthma	40
♦	Patients With Gout	40
♦	Patients Undergoing Surgery	40
♦	Miscellaneous Causes for Increased Blood Pressure	41
♦	Cocaine	41
♦	Lithotripsy	41
♦	Cyclosporine	41
♦	Erythropoietin	42
♦	REFERENCES	43
♦	GLOSSARY	49

LIST OF TABLES

Table 1. Hypertension Awareness, Treatment, and Control Rates	1	♦
Table 2. Classification of Blood Pressure for Adults Age 18 Years and Older	4	♦
Table 3. Manifestations of Target-Organ Disease	5	
Table 4. Recommendations for Followup Based on Initial Set of Blood Pressure Measurements for Adults Age 18 and Older	6	♦
Table 5. Situations in Which Automated Noninvasive Ambulatory Blood Pressure Monitoring Devices May Be Useful	7	♦
Table 6. Lifestyle Modifications for Hypertension Control and/or Overall Cardiovascular Risk	14	♦
Table 7. Antihypertensive Agents	18	♦
Table 8. Antihypertensive Drug Therapy: Individualization Based on Special Considerations	21	♦
Table 9. Selected Drug Interactions With Antihypertensive Therapy	22	♦
Table 10. Adverse Drug Effects	24	♦
Table 11. Causes for Lack of Responsiveness to Therapy	26	
Table 12. Management of the Hypertensive Crisis: Emergencies and Urgencies	28	♦
Table 13. Preventing, Monitoring, and Addressing Problems of Adherence	30	♦
Table 14. Classification of Hypertension in the Young by Age Group	32	
Table 15. Effects of Therapy in Older Hypertensive Patients	36	♦

LIST OF FIGURES

Figure 1. Percent Decline in Age-Adjusted Mortality Rates Since 1972	1	♦
Figure 2. Percent Decline in Age-Adjusted Mortality Rates for Coronary Heart Disease by Race and Sex Since 1972	2	♦
Figure 3. Percent Decline in Age-Adjusted Mortality Rates for Stroke by Race and Sex Since 1972	2	♦
Figure 4. Treatment Algorithm	16	♦

FOREWORD

This fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure—approved by the National High Blood Pressure Education Program Coordinating Committee on the 20th Anniversary of the program—aims to contribute to progress in the primary prevention and control of high blood pressure.

Like its predecessors, this document builds on the available scientific evidence regarding the detection, evaluation, and treatment of hypertension. More information is available today to guide clinicians and community programs in preventing and managing this important public health problem. However, this increase in information makes clinical choices increasingly complex. Thus the need for consensus becomes even more important.

The purpose of this report is to guide:

- ❖ Health professionals participating in the many community high blood pressure control programs.

This report has several new features:

- ❖ Prevalence, awareness, treatment, and control rates for high blood pressure are reported from the 1988-1991 National Health and Nutrition Examination Survey (NHANES III). These are the first new data in more than a decade in this area.
- ❖ A new classification schema of blood pressure that includes systolic as well as diastolic levels is proposed to help convey the impact of high blood pressure risk for cardiovascular disease. Many believe the previously used classification, particularly the term “mild hypertension,” sounded complacent and lacked sufficient emphasis and urgency.
- ❖ An expanded section on primary prevention translates a growing body of knowledge about preventing the disease into recommendations for action.
- ❖ The list of agents that are suitable for initial monotherapy has been expanded—from diuretics, beta-blockers, calcium antagonists, and angiotensin converting enzyme inhibitors—to include the α_1 -receptor blockers and the alpha-beta blocker.
- ❖ Because diuretics and beta-blockers are the only classes of drugs that have been used in long-term controlled clinical trials and shown to reduce morbidity and mortality, they are recommended as first-choice agents unless they are contraindicated or unacceptable, or unless there are special indications for other agents.

- ❖ Practicing physicians and other health professionals in their care of hypertensive patients.

-

Director

National Heart, Lung,
and Blood Institute

MEMBERS OF THE JOINT NATIONAL COMMITTEE ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD PRESSURE

Chairman: Ray W. Gifford, Jr., M.D.
Vice Chairman
Division of Medicine
Cleveland Clinic Foundation
Cleveland, Ohio

Parent Committee

Michael H. Alderman, M.D.
Professor and Chairman
Department of Epidemiology and
Social Medicine
Albert Einstein College of Medicine
Bronx, New York

Aram V. Chobanian, M.D.
Dean and Professor of Medicine
Boston University School of Medicine
Boston, Massachusetts

Susanna L. Cunningham, Ph.D., R.N.
Associate Professor
School of Nursing
University of Washington
Seattle, Washington

Harriet P. Dustan, M.D.
Emeritus Professor of Medicine
University of Alabama School of Medicine
Essex, Vermont

Charles K. Francis, M.D.
Professor of Clinical Medicine
College of Physicians and Surgeons
Columbia University
Director, Department of Medicine
Harlem Hospital Center
New York, New York

Edward D. Frohlich, M.D.
Vice President for Academic Affairs
Alton Ochsner Medical Foundation
New Orleans, Louisiana

Norman M. Kaplan, M.D.
Professor of Internal Medicine
Southwestern Medical School
University of Texas
Dallas, Texas

R. Jerry Mann, M.D.
Assistant Professor
Department of Family and
Community Medicine
University of Arkansas for Medical
Sciences
Little Rock, Arkansas

Marvin Moser, M.D.
Clinical Professor of Medicine
Yale University School of Medicine
Senior Medical Adviser
National High Blood Pressure
Education Program
White Plains, New York

William A. Nickey, D.O.
Professor of Medicine
Chairman, Division of Nephrology and
Hypertension
Osteopathic Medical Center of Philadelphia
Philadelphia, Pennsylvania

H. Mitchell Perry, Jr., M.D.
Physician Coordinator for Hypertension
VA Central Office, Washington, D.C.
Director, Hypertension Division
Washington University School of Medicine
St. Louis, Missouri

James W. Reed, M.D., F.A.C.P.
Professor and Chairman
Department of Medicine
Morehouse School of Medicine
Atlanta, Georgia

Sheldon G. Sheps, M.D.
Chair, Division of Hypertension and
Internal Medicine
Professor of Medicine
Mayo Medical School and Clinic
Rochester, Minnesota

Jeremiah Stamler, M.D.
Professor Emeritus
Department of Community Health and
Preventive Medicine
Northwestern University Medical School
Chicago, Illinois

♦ **Subcommittee on Clinical Evaluation and
Public Health Aspects**

- ♦ **Chairman:** Jeremiah Stamler, M.D.
Professor Emeritus
Department of Community Health and
Preventive Medicine
Northwestern University Medical School
Chicago, Illinois
- ♦ Michael H. Alderman, M.D.
Professor and Chairman
Department of Epidemiology and
Social Medicine
Albert Einstein College of Medicine
Bronx, New York
- ♦ Clarice Brown, M.S.
Coordinator, Data Analysis and
Program Evaluation
Office of Prevention, Education, and Control
National Heart, Lung, and Blood Institute
National Institutes of Health
Bethesda, Maryland
- ♦ Susanna L. Cunningham, Ph.D., R.N.
Associate Professor
School of Nursing
University of Washington
Seattle, Washington
- ♦ Jeffrey Cutler, M.D., M.P.H.
Chief, Prevention and Demonstration
Research Branch
Division of Epidemiology and
Clinical Applications
National Heart, Lung, and Blood Institute
National Institutes of Health
Bethesda, Maryland
- ♦ William R. Harlan, M.D.
Associate Director for Disease Prevention
Office of the Director
National Institutes of Health
Bethesda, Maryland
- ♦ Michel Ibrahim, M.D., M.P.H., Ph.D.
Dean, School of Public Health
University of North Carolina—Chapel Hill
Chapel Hill, North Carolina
- ♦ Stevo Julius, M.D., Sc.D.
Professor of Internal Medicine and
Physiology
Department of Internal Medicine
Chief, Division of Hypertension
The University of Michigan
Ann Arbor, Michigan

Lewis H. Kuller, M.D., Dr.P.H.
Professor and Chairperson
Department of Epidemiology
Graduate School of Public Health
University of Pittsburgh
Pittsburgh, Pennsylvania

David M. Levine, M.D., Sc.D., M.P.H.
Director, Division of Internal Medicine and
Cardiovascular Research
Training Program
The Johns Hopkins School of Medicine
Baltimore, Maryland

Robert S. Murphy, M.S.P.H.
Director, Division of Health
Examination Statistics
National Center for Health Statistics
Centers for Disease Control
Hyattsville, Maryland

James D. Neaton, Ph.D.
Associate Professor of Biostatistics
Division of Biostatistics
School of Public Health
University of Minnesota
Minneapolis, Minnesota

Richard Remington, Ph.D.*
Emeritus Professor
Department of Preventive Medicine and
Environmental Health
School of Medicine
University of Iowa
Iowa City, Iowa

Sheldon G. Sheps, M.D.
Chair, Division of Hypertension and
Internal Medicine
Professor of Medicine
Mayo Medical School and Clinic
Rochester, Minnesota

Fran C. Wheeler, Ph.D.
Director, Center for Health Promotion
South Carolina Department of Health and
Environmental Control
Columbia, South Carolina

Paul K. Whelton, M.D., M.Sc.
Professor of Epidemiology and Medicine
Director, Welch Center for Prevention,
Epidemiology, and Clinical Research
The Johns Hopkins Medical Institutions
Baltimore, Maryland

*Deceased

Subcommittee on Pharmacologic Treatment

Chairman: Edward D. Frohlich, M.D.
Vice President for Academic Affairs
Alton Ochsner Medical Foundation
New Orleans, Louisiana

Vito M. Campese, M.D.
Professor of Medicine
Department of Medicine
Division of Nephrology
University of Southern California
Medical Center
Los Angeles, California

Barry L. Carter, Pharm.D.
Associate Professor and Assistant Head
for Ambulatory Care
Department of Pharmacy Practice
College of Pharmacy
University of Illinois at Chicago
Chicago, Illinois

Aram V. Chobanian, M.D.
Dean and Professor of Medicine
Boston University School of Medicine
Boston, Massachusetts

Harriet P. Dustan, M.D.
Emeritus Professor of Medicine
University of Alabama School of Medicine
Essex, Vermont

Richard Grimm, Jr., M.D., Ph.D.
Associate Professor
Cardiovascular Division
School of Medicine
University of Minnesota
Minneapolis, Minnesota

Marvin Moser, M.D.
Clinical Professor of Medicine
Yale University School of Medicine
Senior Medical Adviser
National High Blood Pressure
Education Program
White Plains, New York

William A. Nicky, D.O.
Professor of Medicine
Chairman, Division of Nephrology and
Hypertension
Osteopathic Medical Center of Philadelphia
Philadelphia, Pennsylvania

Alan Nies, M.D.
Professor of Medicine and Pharmacology
Head, Division of Clinical Pharmacology
University of Colorado
Denver, Colorado

Suzanne Oparil, M.D.
Director, Hypertension Program
Division of Cardiovascular Disease
University of Alabama at Birmingham
Birmingham, Alabama

Jay M. Sullivan, M.D.
Professor of Medicine
Chief, Division of Cardiovascular Diseases
University of Tennessee
Memphis, Tennessee

Donald G. Vidt, M.D.
Senior Physician, Department of
Hypertension and Nephrology
Cleveland Clinic Foundation
Cleveland, Ohio

Subcommittee on Lifestyle Modifications

Chairman: Norman M. Kaplan, M.D.
Professor of Internal Medicine
Southwestern Medical School
University of Texas
Dallas, Texas

Henry R. Black, M.D.
Charles J. and Margaret Roberts Professor
Chairman, Department of
Preventive Medicine
Professor of Internal Medicine
Rush-Presbyterian-St. Luke's
Medical Center
Chicago, Illinois

Steven N. Blair, P.E.D.
Director, Epidemiology
The Institute for Aerobics Research
Dallas, Texas

M. Donald Blaufox, M.D., Ph.D.
Professor and Chairman
Department of Nuclear Medicine
Professor of Medicine
Albert Einstein College of Medicine
Montefiore Medical Center
Bronx, New York

Nancy D. Ernst, M.S., R.D.
Nutrition Coordinator
National Heart, Lung, and Blood Institute
National Institutes of Health
Bethesda, Maryland

- ♦ Theodore A. Kotchen, M.D.
E.B. Flink Professor and Chairman
- ♦ Department of Medicine
West Virginia University
Morgantown, West Virginia
- Michael A. Moore, M.D.
- ♦ Associate Clinical Professor of Medicine
Bowman Gray School of Medicine
- ♦ Clinical Professor of Medicine
School of Medicine
University of North Carolina—Chapel Hill
- ♦ Nephrologist, Danville Urologic Clinic
Danville, Virginia
- ♦ John A. Spittell, Jr., M.D.
Professor of Medicine
- ♦ Mayo Medical School
Consultant, Cardiovascular Diseases
- ♦ Mayo Clinic
Rochester, Minnesota

- ♦ Mary Winston, Ed.D., R.D.
Senior Science Consultant
- ♦ Science Division
Office of Scientific Affairs
- ♦ American Heart Association
Dallas, Texas

♦ Subcommittee on Special Populations and Situations

- ♦ **Chairman:** James W. Reed, M.D., F.A.C.P.
Professor and Chairman
- ♦ Department of Medicine
Morehouse School of Medicine
Atlanta, Georgia
- ♦ Phyllis August, M.D.
Associate Professor of Medicine and
- ♦ Associate Professor of Medicine in
Obstetrics and Gynecology
- ♦ Cardiovascular Center
New York Hospital
Cornell University Medical College
New York, New York
- ♦ Kenneth Berge, M.D.
Professor of Medicine
Mayo Medical School
- ♦ Community Internal Medicine
Mayo Clinic
Rochester, Minnesota
- ♦ Richard Devereux, M.D.
Associate Professor of Medicine
New York Hospital
- ♦ Cornell University Medical College
New York, New York

Karen Donato, M.S., R.D.
Coordinator, NHLBI Obesity
Education Initiative
Office of Prevention, Education, and Control
National Heart, Lung, and Blood Institute
National Institutes of Health
Bethesda, Maryland

Bonita Falkner, M.D.
Professor of Pediatrics
Medical College of Pennsylvania
Philadelphia, Pennsylvania

Mae K. Goins, R.N.
Administrator
Family Health Center
Hialeah, Florida

Clarence E. Grim, M.D.
Professor of Medicine
Director, Hypertension Research Center
Charles R. Drew University of
Medicine and Science
Los Angeles, California

W. Dallas Hall, M.D.
Professor of Medicine
Director, Division of Hypertension
Department of Medicine
Emory University
Atlanta, Georgia

Michael J. Horan, M.D., Sc.M.
Associate Director for Cardiology
Division of Heart and Vascular Diseases
National Heart, Lung, and Blood Institute
National Institutes of Health
Bethesda, Maryland

Shiriki K. Kumanyika, Ph.D., M.P.H.
Associate Professor
Associate Director for Epidemiology
Center for Biostatistics and Epidemiology
College of Medicine
Pennsylvania State University
Hershey, Pennsylvania

H. Mitchell Perry, Jr., M.D.
Physician Coordinator for Hypertension
VA Central Office, Washington, D.C.
Director, Hypertension Division
Washington University School of Medicine
St. Louis, Missouri

Jerome G. Porush, M.D.
Chief, Division of Nephrology and
Hypertension
Professor of Medicine
The Brookdale Hospital Medical Center
Brooklyn, New York

Otelio S. Randall, M.D.
Associate Professor of Medicine
Director of CCU, Hypertension Section,
and Preventive Cardiology Program
Howard University Hospital
Washington, D.C.

Kathryn A. Taubert, Ph.D.
Science Consultant
Office of Scientific Affairs
American Heart Association
Dallas, Texas

Staff

Edward J. Roccella, Ph.D., M.P.H.
Coordinator
National High Blood Pressure
Education Program
Office of Prevention, Education, and Control
National Heart, Lung, and Blood Institute
National Institutes of Health
Bethesda, Maryland

Gail T. Brito, R.N.
NHBPEP Contract Manager
NHLBI Education Programs
Support Contract
University Research Corporation
Bethesda, Maryland

Acknowledgments

Raymond A. Borazanian
Editorial Assistant
Department of Hypertension and
Nephrology
Cleveland Clinic Foundation
Cleveland, Ohio

Vicki Burt, R.N., Sc.M.
Chief, Survey Planning and
Development Branch
Division of Health Examination Statistics
National Center for Health Statistics
Centers for Disease Control
Hyattsville, Maryland

Lisa J. Harris
Production Coordinator
NHLBI Education Programs
Support Contract
University Research Corporation
Bethesda, Maryland

Ronald J. Prineas, M.D., Ph.D.
Professor and Chair
Department of Epidemiology and
Public Health
School of Medicine
University of Miami
Miami, Florida

Christopher T. Sempos, Ph.D.
Chief, Longitudinal Studies Branch
Division of Health Examination Statistics
National Center for Health Statistics
Centers for Disease Control
Hyattsville, Maryland

Robert Temple, M.D.
Director, Office of Drug Research and
Review
Center for Drug Evaluation and Research
Food and Drug Administration
Rockville, Maryland

Dorothy C. Zankel, M.Ed.
Library Services Coordinator
NHLBI Education Programs
Support Contract
University Research Corporation
Bethesda, Maryland

♦ THE NATIONAL
♦ HIGH BLOOD PRESSURE
♦ EDUCATION PROGRAM
♦ COORDINATING COMMITTEE

♦ Member Organizations

- ♦ American Academy of Family Physicians
- ♦ American Academy of Insurance Medicine
- ♦ American Academy of Ophthalmology
- ♦ American Academy of Physician Assistants
- ♦ American Association of Occupational Health Nurses
- ♦ American College of Cardiology
- ♦ American College of Chest Physicians
- ♦ American College of Occupational and Environmental Medicine
- ♦ American College of Physicians
- ♦ American College of Preventive Medicine
- ♦ American Dental Association
- ♦ American Diabetes Association
- ♦ American Dietetic Association
- ♦ American Heart Association
- ♦ American Hospital Association
- ♦ American Medical Association
- ♦ American Nurses' Association, Inc.
- ♦ American Optometric Association
- ♦ American Osteopathic Association
- ♦ American Pharmaceutical Association
- ♦ American Podiatric Medical Association
- ♦ American Public Health Association

- American Red Cross
- American Society of Hospital Pharmacists
- American Society of Hypertension
- Association of Black Cardiologists
- Citizens for Public Action on High Blood Pressure and Cholesterol, Inc.
- International Society on Hypertension in Blacks

- National Black Nurses' Association, Inc.
- National Heart, Lung, and Blood Institute
Ad Hoc Committee on Minority Populations
- National Hypertension Association, Inc.
- National Kidney Foundation
- National Medical Association
- National Optometric Association
- National Stroke Association
- Society for Nutrition Education

Federal Agencies

- Agency for Health Care Policy and Research
- Health Care Financing Administration
- Health Resources and Services Administration
- National Center for Health Statistics, Centers for Disease Control
- National Heart, Lung, and Blood Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
- Veterans Administration

CHAPTER I

INTRODUCTION

Since the inception of the National High Blood Pressure Education Program (NHBPEP) in 1972, remarkable progress has been made in detecting, treating, and controlling hypertension. In the last two decades the number of hypertensives aware of their condition has increased dramatically. In addition, the percentage of hypertensives taking medication and controlling their condition has also improved substantially (see Table 1). Concomitantly, notable and sustained declines in cardiovascular mortality have occurred among all adult population strata. During the last two decades, the mortality rate from the number one cause of death, coronary heart disease, has decreased about 50 percent, and that from stroke has fallen by 57 percent (National Center for Health Statistics [NCHS] data calculated by National Heart, Lung, and Blood Institute [NHLBI] staff) (see Figures 1, 2, and 3). Because high blood pressure is one of the major risk factors for coronary heart disease, and the most impor-

tant risk factor for the cerebrovascular diseases, it is a reasonable inference that progress in the detection, treatment, and control of hypertension has contributed substantially to these mortality declines.

TABLE 1. HYPERTENSION* AWARENESS, TREATMENT, AND CONTROL RATES

	1971-72 [†]	1974-75 [†]	1976-80**	1988-91 [§]
Aware: percentage of hypertensives told by physician	51	64	(54) 73	(65) 84
Treated: percentage of hypertensives on medication	36	34	(33) 56	(49) 73
Controlled: percentage of hypertensives with blood pressure <160/95 mm Hg on one occasion measurement and reported currently taking antihypertensive medications	16	20	(11) 34	(21) 55

Note: Numbers in () are percentage at 140/90 mm Hg.


* Defined as $\geq 160/95$ mm Hg on one occasion measurement or reported currently taking antihypertensive medication.

Source: [†] NHANES I[†]

^{**} NHANES II[†]

[§] NHANES III unpublished data provided by the Centers for Disease Control, National Center for Health Statistics.


FIGURE 1. PERCENT DECLINE IN AGE-ADJUSTED MORTALITY RATES SINCE 1972



* Provisional data for 1990.

Source: NCHS data calculated by NHLBI.

FIGURE 2. PERCENT DECLINE IN AGE-ADJUSTED MORTALITY RATES FOR CORONARY HEART DISEASE BY RACE AND SEX SINCE 1972




* Provisional data for 1990. Race/sex data for 1990 not yet available.

Source: NCHS data calculated by NHLBI.

During the last two decades, the mortality rate from coronary heart disease has decreased about 50 percent, and that from stroke has fallen by 57 percent.

FIGURE 3. PERCENT DECLINE IN AGE-ADJUSTED MORTALITY RATES FOR STROKE BY RACE AND SEX SINCE 1972



* Provisional data for 1990. Race/sex data for 1990 not yet available.

Source: NCHS data calculated by NHLBI.

CHAPTER II

CLINICAL EVALUATION AND PUBLIC HEALTH ASPECTS OF HIGH BLOOD PRESSURE

As many as 50 million Americans have elevated blood pressure (systolic blood pressure 140 mm Hg or greater and/or diastolic blood pressure 90 mm Hg or greater) or are taking antihypertensive medication. This estimate is derived from a random sample of American adults (NHANES III), plus extrapolations from large data sets on the young applied to the 1990 census population and represents a decrease in the number of hypertensives reported one decade ago (NHANES II).

The prevalence of high blood pressure increases with age, is greater for blacks than for whites, and in both races is greater in less educated than more educated people. It is especially prevalent and devastating in lower socioeconomic groups. In young adulthood and early middle age, high blood pressure prevalence is greater for men than for women; thereafter, the reverse is true. Blacks and whites in the southeastern United States have a greater prevalence of high blood pressure and greater stroke death rates

than do blacks and whites in other areas of the country.³ Nonfatal and fatal cardiovascular diseases (CVD)—including coronary heart disease (CHD) and stroke—as well as renal disease, and all-cause mortality, increase progressively with higher levels of both systolic blood pressure (SBP) and diastolic blood pressure (DBP). These relationships are strong, continuous, graded, consistent, independent, predictive, and etiologically significant. In the general population, risks are lowest for adults with an average SBP less than 120 mm Hg and an average DBP less than 80 mm Hg. Higher levels of either SBP or DBP or both together are associated with increased risks of morbidity, disability, and mortality. At every level of DBP, risks are greater with higher levels of SBP. Recent data underscore the importance of attention to SBP, as well as to DBP, in diagnosis and therapy. In both middle-aged and older persons, increases in CVD are associated with elevated SBP, not only when DBP is also high but when DBP is normal—the entity of isolated systolic hypertension.

NEW CLASSIFICATION OF HIGH BLOOD PRESSURE

Table 2 provides a new classification of adult blood pressure based on impact on risk. The traditional terms “mild hypertension” and “moderate hypertension” failed to convey the major impact of high blood pressure on risk of CVD. High normal blood pressure is included as a category because persons with SBP and/or DBP in these ranges are at increased risk of developing definite high blood pressure and of experiencing nonfatal and fatal cardiovascular events, compared with otherwise similar persons with lower blood pressures. Individuals

*The prevalence
of high
blood pressure
increases with
age, is greater for
blacks than
whites, and in
both races is
greater in less
educated than
more educated
people.*

The traditional terms “mild hypertension” and “moderate hypertension” failed to convey the major impact of high blood pressure on risk of CVD.

- ♦ with high normal blood pressure should be monitored frequently and counseled in regard to lifestyle measures that can reduce their blood pressure; although pharmacologic therapy is rarely if ever needed.^{4,5}
- ♦ The new classification presented in Table 2 describes stages of blood pressure. All stages of hypertension are associated with increased risk of nonfatal and fatal CVD events and renal disease. The higher the blood pressure, the greater the risk. High blood pressure Stage 1, previously termed “mild,” is the most common form of high blood pressure in the adult population and is therefore responsible for a large

proportion of the excess morbidity, disability, and mortality attributable to hypertension. All stages of hypertension warrant effective long-term therapy.

Cardiovascular risks relate to blood pressure elevation, dyslipidemia, cigarette use, diabetes mellitus, physical inactivity, and obesity. Detection and treatment of cardiovascular risk factors are key to managing persons with high blood pressure. Risks of CVD at any level of high blood pressure are increased several-fold for persons with target-organ disease (TOD) as described in Table 3.

DETECTION AND CONFIRMATION

Hypertension control begins with detection and requires continued surveillance. Health care professionals are strongly encouraged to measure blood pressure at each patient visit.

Measurement

Hypertension should not be diagnosed on the basis of a single measurement. Initial elevated readings should be confirmed on at least two subsequent visits during one to several weeks (unless SBP is 210 mm Hg or greater, and/or DBP is 120 mm Hg or greater), with average levels of DBP of 90 mm Hg or greater and/or SBP of 140 mm Hg or greater required for diagnosis (see Table 4).

Blood pressure should be measured in such a manner that values obtained are representative of patients' usual levels. The following techniques are recommended:

- ❖ Patients should be seated with their arm bared, supported, and at heart level. They should not have smoked or ingested caffeine within 30 minutes prior to measurement.

TABLE 2. CLASSIFICATION OF BLOOD PRESSURE FOR ADULTS AGE 18 YEARS AND OLDER*

Category	Systolic (mm Hg)	Diastolic (mm Hg)
Normal†	<130	<85
High normal	130-139	85-89
Hypertension**		
STAGE 1 (Mild)	140-159	90-99
STAGE 2 (Moderate)	160-179	100-109
STAGE 3 (Severe)	180-209	110-119
STAGE 4 (Very Severe)	≥210	≥120

* Not taking antihypertensive drugs and not acutely ill. When systolic and diastolic pressures fall into different categories, the higher category should be selected to classify the individual's blood pressure status. For instance, 160/92 mm Hg should be classified as Stage 2, and 180/120 mm Hg should be classified as Stage 4. Isolated systolic hypertension (ISH) is defined as SBP ≥140 mm Hg and DBP <90 mm Hg and staged appropriately (e.g., 170/85 mm Hg is defined as Stage 2 ISH).

† Optimal blood pressure with respect to cardiovascular risk is SBP <120 mm Hg and DBP <80 mm Hg. However, unusually low readings should be evaluated for clinical significance.

** Based on the average of two or more readings taken at each of two or more visits following an initial screening.

Note: In addition to classifying stages of hypertension based on average blood pressure levels, the clinician should specify presence or absence of target-organ disease and additional risk factors. For example, a patient with diabetes and a blood pressure of 142/94 mm Hg plus left ventricular hypertrophy should be classified as “Stage 1 hypertension with target-organ disease (left ventricular hypertrophy) and with another major risk factor (diabetes).” This specificity is important for risk classification and management.

- ❖ Measurement should begin after 5 minutes of rest.
- ❖ The appropriate cuff size must be used to ensure an accurate measurement. The bladder should nearly (at least 80%) or completely encircle the arm.
- ❖ Measurements should be taken with a mercury sphygmomanometer, a recently calibrated aneroid manometer, or a calibrated electronic device.
- ❖ Both systolic and diastolic pressures should be recorded. The disappearance of sound (phase V) should be used for the diastolic reading.
- ❖ Two or more readings separated by 2 minutes should be averaged. If the first two readings differ by more than 5 mm Hg, additional readings should be obtained.

Patients should be informed and taught the meaning of their blood pressure readings and advised of the need for periodic remeasurement. Table 4 provides followup advice based on the *initial* set of blood pressure measurements. For more information regarding blood pressure measurement, refer to the American Heart Association's "Recommendations for Human Blood Pressure Determination by Sphygmomanometers"⁶ and the American Society of Hypertension's "Recommendations for Routine Blood Pressure Measurement by Indirect Cuff Sphygmomanometry."⁷

Confirmation and Followup

Repeated blood pressure measurements will determine whether initial elevations persist and require close observation or prompt attention, or whether they have returned to normal and need only periodic remeasurement. Initial blood pressure readings that are markedly

TABLE 3. MANIFESTATIONS OF TARGET-ORGAN DISEASE

Organ System	Manifestations
Cardiac	Clinical, electrocardiographic, or radiologic evidence of coronary artery disease Left ventricular hypertrophy or "strain" by electrocardiography or left ventricular hypertrophy by echocardiography Left ventricular dysfunction or cardiac failure
Cerebrovascular	Transient ischemic attack or stroke
Peripheral vascular	Absence of one or more major pulses in the extremities (except for dorsalis pedis) with or without intermittent claudication; aneurysm
Renal	Serum creatinine $\geq 130 \mu\text{mol/L}$ (1.5 mg/dL) Proteinuria (1+ or greater) Microalbuminuria
Retinopathy	Hemorrhages or exudates, with or without papilledema

elevated (i.e., DBP 120 mm Hg or greater, or SBP 210 mm Hg or greater) or are associated with evidence of TOD may require immediate drug therapy. The timing of subsequent readings should be based on the initial blood pressure level (see Table 4) as well as prior diagnosis and treatment of CVD and risk factors.

HOME MEASUREMENT AND AMBULATORY AUTOMATIC MONITORING OF BLOOD PRESSURE

Blood pressure measurements obtained in the health care setting may not reflect a patient's usual or average blood pressure. Using inexpensive manual or semiautomatic devices, blood pressure monitoring at home and/or work (by the patient, family, or friends) is often helpful in evaluating the severity of hypertension and judging the effectiveness of therapy. Each device must be cali-

Patients should be informed and taught the meaning of their blood pressure readings and advised of the need for periodic remeasurement.

- ♦ brated initially and then at least yearly.
- ♦ Each user must be carefully instructed in the technique of measurement and
- ♦ rechecked periodically.
- ♦ Fully automatic, lightweight, portable, unobtrusive blood pressure recording
- ♦ devices are now available that can measure and store blood pressure and heart
- ♦ rate data for 24 hours or longer. Clinical situations for which noninvasive ambulatory blood pressure monitoring (ABPM)
- ♦ may be useful are shown in Table 5.⁸ There is increasing evidence that damage
- ♦ to target organs (heart, kidney, brain, and large arteries) correlates better with
- ♦ out-of-office measurements, including those by ABPM, than with office measurements.⁹⁻¹¹ While ABPM is a unique tool for
- ♦ research and for extended assessment of particular hypertensive patients with
- ♦ special clinical problems, it is not neces-

sary for the routine diagnosis and management of most patients.

EVALUATION

Clinical evaluation of patients with confirmed hypertension should help answer the following questions:

1. Does the patient have primary or secondary (possibly reversible) hypertension?
2. Is target-organ disease present?
3. Are cardiovascular risk factors present in addition to high blood pressure?

Examination should seek to eliminate the possibility of rare secondary hypertension.¹² Physical findings suggestive of secondary hypertension include abdominal or flank masses (polycystic kidneys); abdominal bruits, particularly those that lateralize or have a diastolic component (renovascular disease); delayed or absent femoral arterial pulses and decreased blood pressure in lower extremities compared with the upper extremities (aortic coarctation); truncal obesity with purple striae (Cushing's syndrome); and tachycardia, tremor, orthostatic hypotension, sweating, and pallor (pheochromocytoma). Additional diagnostic procedures may be indicated to seek causes of secondary hypertension, particularly in patients (1) whose age, history, physical examination, severity of hypertension, or initial laboratory findings suggest secondary hypertension; (2) whose blood pressures are responding poorly to drug therapy; (3) with well-controlled hypertension whose blood pressures begin to increase; (4) with accelerated or malignant hypertension; and (5) with sudden onset of hypertension.

**TABLE 4. RECOMMENDATIONS FOR FOLLOWUP
BASED ON INITIAL SET OF BLOOD PRESSURE MEASUREMENTS
FOR ADULTS AGE 18 AND OLDER**

Initial Screening Blood Pressure (mm Hg)*		Followup Recommended†
Systolic	Diastolic	
<130	<85	Recheck in 2 years
130-139	85-89	Recheck in 1 year**
140-159	90-99	Confirm within 2 months
160-179	100-109	Evaluate or refer to source of care within 1 month
180-209	110-119	Evaluate or refer to source of care within 1 week
≥210	≥120	Evaluate or refer to source of care immediately

* If the systolic and diastolic categories are different, follow recommendation for the shorter time followup (e.g., 160/85 mm Hg should be evaluated or referred to source of care within 1 month).

† The scheduling of followup should be modified by reliable information about past blood pressure measurements, other cardiovascular risk factors, or target-organ disease.

** Consider providing advice about lifestyle modifications (see Chapter III).

The remainder of the clinical evaluation primarily addresses target-organ disease and other cardiovascular risk factors. Such information along with degree of blood pressure elevation will determine absolute risk level and, therefore, how aggressively blood pressure should be reduced.

MEDICAL HISTORY

A medical history should include the following:

- ❖ Family history of high blood pressure, premature CHD, stroke, CVD, diabetes mellitus, and dyslipidemia
- ❖ Patient history or symptoms of cardiovascular, cerebrovascular, or renal disease; diabetes mellitus; dyslipidemia; or gout
- ❖ Known duration and levels of elevated blood pressure
- ❖ History of weight gain, leisure-time physical activities, smoking or other tobacco use
- ❖ Dietary assessment including sodium intake, alcohol use, and intake of cholesterol and saturated fats
- ❖ Results and side effects of previous antihypertensive therapy
- ❖ Symptoms suggesting secondary hypertension
- ❖ Psychosocial and environmental factors (e.g., family situation, employment status and working conditions, educational level) that may influence blood pressure control.

Clinicians should obtain a history of all prescribed and over-the-counter medications. Some medications can raise blood pressure and/or interfere with the effectiveness of antihypertensive drugs. These

TABLE 5. SITUATIONS IN WHICH AUTOMATED NONINVASIVE AMBULATORY BLOOD PRESSURE MONITORING DEVICES MAY BE USEFUL

“Office” or “white-coat” hypertension: blood pressure repeatedly elevated in office setting but repeatedly normal out of the office

Evaluation of drug resistance

Evaluation of nocturnal blood pressure changes

Episodic hypertension

Hypotensive symptoms associated with antihypertensive medications or autonomic dysfunction

Carotid sinus syncope and pacemaker syndromes*

* Along with electrocardiographic monitoring.

drugs include, but are not limited to, oral contraceptives, steroids, nonsteroidal anti-inflammatory drugs (NSAID's), nasal decongestants and other cold remedies, appetite suppressants, cyclosporine, erythropoietin, tricyclic antidepressants, and monoamine oxidase inhibitors.

PHYSICAL EXAMINATION

The initial physical examination should include the following:

- ❖ Two or more blood pressure measurements separated by 2 minutes with the patient either supine or seated, and after standing for at least 2 minutes
- ❖ Verification in the contralateral arm (if values are different, the higher value should be used)
- ❖ Measurement of height and weight
- ❖ Funduscopic examination (with pupil dilatation if necessary) for arteriolar narrowing, arteriovenous nicking, hemorrhages, exudates, or papilledema

Lifestyle factors include a high sodium intake, an excessive consumption of calories, physical inactivity, excessive alcohol consumption, and a low intake of potassium — they form the basis for intervention strategies which have shown promise in the prevention of high blood pressure.

- ♦ ❖ Examination of the neck for carotid bruits, distended veins, or an enlarged thyroid gland
- ♦ ❖ Examination of the heart for increased rate, increased size, precordial heave, clicks, murmurs, arrhythmias, and third(s₃) and fourth(s₄) heart sounds
- ♦ ❖ Examination of the abdomen for bruits, enlarged kidneys, masses, and abnormal aortic pulsation
- ♦ ❖ Examination of the extremities for diminished or absent peripheral arterial pulsations, bruits, and edema
- ♦ ❖ Neurologic assessment.

LABORATORY TESTS AND DIAGNOSTIC PROCEDURES

- ♦ A few laboratory tests should be performed routinely before initiating therapy. These include urinalysis; complete blood count, blood glucose (fasting, if possible), potassium, calcium, creatinine, uric acid, cholesterol (total and high-density lipoprotein) and triglyceride levels (an automated blood chemistry is usually less expensive); and electrocardiography.
- ♦ Some of these tests are needed for determining severity of CVD and possible causes of hypertension. Others relate to cardiovascular risk factors or provide baseline values for judging biochemical effects of therapy. Other tests—such as urinary microalbumin determination, assessment of cardiac anatomy and function by echocardiography, and plasma renin/urinary sodium determination—are additional measures occasionally useful
- ♦ in assessing cardiovascular status in selected cases.

From the history, physical exam, and laboratory tests, an assessment of absolute risk should be made. Tables, formulas, and

various computer software to calculate CVD risks using data from epidemiologic studies are available.¹³

PRIMARY PREVENTION OF HIGH BLOOD PRESSURE

Primary prevention of hypertension can be accomplished by application of interventions to the general population (population strategy) with the objective of achieving a downward shift in the distribution of blood pressure. This approach can be complemented by special attempts to lower blood pressure among those who are most likely to develop hypertension (targeted strategy). The latter include persons with a high normal blood pressure, a family history of hypertension, and those with one or more of the several lifestyle factors that are important contributors to age-related increases in blood pressure. These lifestyle factors include a high sodium intake, an excessive consumption of calories, physical inactivity, excessive alcohol consumption, and a low intake of potassium. They form the basis for intervention strategies that have shown promise in the prevention of high blood pressure.⁴ The evidence is less convincing for stress management and for supplementation with calcium, magnesium, fish oils, or fiber, and for alteration in macronutrient consumption. In many instances, however, the data are insufficient to make a final judgment on the potential role of these factors in the primary prevention of hypertension.

Intervention programs conducted in community-based and practice-based settings indicate that the desired lifestyle changes are potentially feasible. Achievement of the intervention goals has, however, been constrained by a number

of societal barriers including a lack of satisfactory food substitutes and the absence of a national campaign to foster adoption of the population-based and targeted intervention strategies necessary to prevent high blood pressure. The NHBPEP is well positioned to provide leadership for such a campaign. Goals of the campaign should include promotion of foods that are lower in sodium and calorie content and higher in potassium content, and promotion of physical activity and moderation in alcohol consumption. To reach these goals, public education to underscore the importance of lifestyle factors in the development of hypertension, as well as enhanced education and support of health care providers to encourage and facilitate their active participation will be necessary. Objectives for national change in the prevalence of factors that increase the public's risk of developing high blood pressure should be established, where they do not yet exist. Finally, additional attention needs to be focused on research questions related to the prevention of high blood pressure. Although challenging, the potential for benefit makes primary prevention of hypertension an important national goal for the next decade.

COMMUNITY PROGRAMS FOR BLOOD PRESSURE CONTROL

Community screening activities are important for population subgroups at especially high risk for developing CVD and with limited access to medical care. Community programs may be an important strategy for primary prevention of hypertension and for monitoring the progress and promoting adherence of hypertensive persons already on therapy.

Ideally, community programs are encouraged to include as many of the following as their resources will allow.

- ❖ Detection, education, and referral for other cardiovascular risk factors.
- ❖ Multiple strategies to improve treatment adherence, including public, patient, and professional education activities incorporating culturally sensitive approaches¹⁴ as well as environmental supports such as informative food labeling, heart healthy menus in restaurants, and safe trails for walking and biking.
- ❖ Multiple sites to reach all segments of the population, including all health care settings, schools, worksites, churches, community centers, supermarkets, and pharmacies.
- ❖ Extensive use of media promotion in conjunction with these activities.¹⁵⁻¹⁷
- ❖ Multiple targets, including individuals and groups with increased cardiovascular risk factors as well as those with “normal” risk factor levels who need education and support to continue to practice preventive behaviors, such as weight control, exercise, and good nutrition.⁴

In the absence of resources for comprehensive efforts, community programs are encouraged to begin modest activities with expansion to more comprehensive programs when possible. Community programs are most effective when they work with clinicians and other health care providers. This coordination occurs only if clinicians are aware of and support the community programs. Advisory boards or community high blood pressure councils can facilitate cooperation among professional agencies, local health departments, voluntary health agencies, hospitals, industry, and other

Community programs are most effective when they work with clinicians and other health care providers.

Newer classes of antihypertensive drugs are up to 30 times more expensive than generic diuretics and beta-blockers.

- ♦ interest groups. These boards or councils can help identify community problems, resources, priorities, solutions to problems, and methods of evaluating program effectiveness.¹⁸ Such community involvement fosters a sense of ownership and acceptance of responsibility for the community's health problems and their solutions.

COST OF CARE

- ♦ Lifelong antihypertensive therapy represents a significant component of the Nation's financial commitment to health. Drug costs can amount to 70 to 80 percent of total expenditure for treating hypertension.¹⁹ Thus, for individual as well as societal reasons, minimizing cost must be an essential component of the health care provider's responsibility.²⁰ Interventions should be commensurate with the risk and potential for benefit in each case. Determinants of cost include the following:
 - ♦ ♦ *Initial evaluation.* Beyond history and physical examination, laboratory evaluations should be done only to the extent necessary to guide individual clinical practice.
 - ♦ ♦ *Followup visits.* The goal of antihypertensive care is to prevent CVD. Frequency of visits and intensity of evaluation and treatment should be the minimum sufficient to achieve and maintain control of blood pressure and other major risk factors and to contain progression of vascular disease.

- ♦ ♦ *Drugs.* Newer classes of antihypertensive drugs are up to 30 times more expensive than generic diuretics and beta-blockers.²⁰ However, the use of diuretics and beta-blockers requires additional surveillance and measurement of changes in blood biochemical and lipid levels that will somewhat increase the cost of their use. Regardless of which drug is chosen, drug dosages and associated costs may be reduced with appropriate patient education/counseling for diet and weight control. In addition, the cost of drugs may be reduced by prescribing scored tablets containing twice the prescribed dosage, when available, and dividing the tablet to achieve the appropriate dose.

- ♦ ♦ *Confirmation strategy.* A strategy that reduces the number of individuals initially identified as having Stage 1 hypertension and needing long-term drug therapy can lead to a substantial reduction in health care costs. Patient self-monitoring of blood pressure and ABPM may prove to be useful and cost-effective in assisting the clinician in making an appropriate diagnosis.²¹ These strategies may identify patients with normal blood pressure outside the office and thereby limit the number requiring treatment; however, controlled clinical trials need to be done to substantiate this.²²

CHAPTER III

TREATMENT

GOAL

The goal of treating patients with hypertension is to prevent morbidity and mortality associated with high blood pressure and to control blood pressure by the least intrusive means possible. This should be accomplished by achieving and maintaining arterial pressure below 140 mm Hg SBP and 90 mm Hg DBP, while concurrently controlling other modifiable cardiovascular risk factors. Further reduction to levels of 130/85 mm Hg may be pursued, with due regard for cardiovascular function, especially in older persons. How far the DBP should be reduced below 85 mm Hg is unclear.²³

LIFESTYLE MODIFICATION

Lifestyle modifications (previously termed nonpharmacologic therapy)—which include weight reduction, increased physical activity, and moderation of dietary sodium and alcohol intake—are used as definitive or adjunctive

therapy for hypertension.^{24,25} They offer some hope for prevention of the disease.^{4,26-28} They are effective in lowering the blood pressure of many people who follow them, and they can also reduce other risk factors for premature CVD. Their capacity to reduce morbidity or mortality in those with elevated blood pressure has not been conclusively documented. However, because of their ability to improve the cardiovascular risk profile, lifestyle modification interventions, properly used, offer multiple benefits at little cost and with minimal risk. Even when not adequate in themselves to control hypertension, they may reduce the number and doses of antihypertensive medications needed to manage the condition.²⁹ Lifestyle modifications are particularly helpful in the large proportion of hypertensive patients who have additional risk factors for premature CVD, especially dyslipidemia or diabetes.³⁰ Therefore, clinicians should vigorously encourage their patients to adopt these lifestyle modifications.

Tobacco Avoidance

Although unrelated to hypertension, cigarette smoking is a major risk factor for CVD, and avoidance of tobacco is essential. Everyone, especially hypertensive patients, should be strongly advised not to smoke. Repetitive counseling, including referral to effective smoking cessation programs, should be provided. Those who continue to smoke may not receive the full degree of protection against CVD from antihypertensive therapy.^{31,32} The nicotine patch or nicotine chewing gum in conjunction with patient counseling may assist the clinician in promoting smoking cessation. Smoking cessation information is available from voluntary health associations and the NHLBI Information Center (P.O. Box 30105, Bethesda, Maryland 20824-0105).

The goal of treating patients with hypertension is to prevent morbidity and mortality associated with high blood pressure and to control blood pressure by the least intrusive means possible.

*Lifestyle
modifications are
used as definitive
or adjunctive
therapy for
hypertension.*

♦ **Weight Reduction**

♦ Excess body weight is correlated closely with increased blood pressure. The deposition of excess fat in the upper body (truncal or abdominal), as evidenced by an increased waist-to-hip ratio above 0.85 in women and 0.95 in men, has also been correlated with hypertension, dyslipidemia, diabetes, and increased coronary heart disease mortality.³³

♦ Weight reduction reduces blood pressure in a large proportion of hypertensive individuals who are more than 10 percent above ideal weight.³⁴ A reduction in blood pressure usually occurs early during a weight loss program, often with as small a weight loss as 10 pounds.³⁵ Weight reduction of overweight hypertensive patients enhances the blood pressure lowering effect of concurrent antihypertensive agents and can significantly reduce concomitant cardiovascular risk factors.

♦ Therefore, all hypertensive patients who are above their ideal weight should initially be placed on an individualized, monitored weight reduction program involving caloric restriction and increased caloric expenditure by regular physical activity. In overweight patients with Stage 1 hypertension, an attempt to control blood pressure with weight loss and other lifestyle modifications should be tried for at least 3 to 6 months prior to initiating pharmacologic therapy. If pharmacologic therapy is needed, the weight loss program should continue to be pursued vigorously. While recidivism is common and can be discouraging, the long-term goal of attenuating age-related weight gain should be kept in mind.

Moderation of Alcohol Intake

Excessive alcohol intake can raise blood pressure and cause resistance to antihypertensive therapy.³⁶ A detailed history of current alcohol consumption should be elicited. Hypertensive patients who drink alcohol-containing beverages should be counseled to limit their daily intake to 1 ounce of ethanol (2 ounces of 100 proof whiskey, 8 ounces of wine, or 24 ounces of beer). Significant hypertension may develop during withdrawal from heavy alcohol consumption, but the pressor effect of alcohol withdrawal reverses a few days after alcohol consumption is reduced.³⁷

Physical Activity

Regular aerobic physical activity, adequate to achieve at least a moderate level of physical fitness, may be beneficial both for prevention and treatment of hypertension. It can also enhance weight loss and functional health status and reduce the risk for CVD and all-cause mortality.³⁸ Sedentary and unfit normotensive individuals have a 20 to 50 percent increased risk of developing hypertension during followup when compared with their more active and fit peers.³⁹

Regular aerobic physical activity can reduce SBP in hypertensive patients by approximately 10 mm Hg.⁴⁰ Effective lowering of blood pressure can be achieved with only moderately intense physical activity (40 to 60 percent of VO_{2max}). Therefore, physical activity need not be complicated or expensive; and, for most sedentary patients, moderate activity such as 30 to 45 minutes of brisk walking three to five times per week will be beneficial. The majority of patients with uncomplicated hypertension can safely increase their level of physical activity without an

extensive medical or physical fitness evaluation. Patients with known cardiac disease or other serious health problems need a more thorough examination, often including an electrocardiogram-monitored exercise test, and may need to be referred to medically supervised rehabilitative exercise programs.

Moderation of Dietary Sodium

Epidemiologic observations and clinical trials support an association between dietary sodium intake and blood pressure. Based on linear regression analysis, within populations, a 100 mmol per day lower average sodium intake was associated with a 2.2 mm Hg lower SBP in 10,000 people,⁴¹ and a 5 to 10 mm Hg lower SBP in multiple other studies involving 47,000 participants.⁴² Furthermore, a 100 mmol per day lower sodium intake was associated with a 9 mm Hg attenuation of the rise of SBP between the ages of 25 and 55 years.⁴³

Multiple therapeutic trials document a reduction of blood pressure in response to reduced sodium intake. In short-term trials, moderate sodium restriction in hypertensive individuals on average has been shown to reduce SBP by 4.9 mm Hg and DBP by 2.6 mm Hg.⁴⁴ In trials involving people aged 50 to 59 and lasting 5 weeks or longer, a 50 mmol per day reduction of sodium intake was associated with an average of a 7 mm Hg reduction in SBP in hypertensive persons and a 5 mm Hg reduction in normotensive people.⁴⁵

The impact of dietary sodium on blood pressure depends on the provision of sodium as the chloride salt. Individuals vary in their blood pressure response to changes in dietary sodium chloride.⁴⁶

Blacks, older people, and patients with hypertension are more sensitive to changes in dietary sodium chloride.^{47,48}

Because the average American consumption of sodium is in excess of 150 mmol per day, moderate dietary sodium chloride reduction to a level of less than 100 mmol per day (less than 6 grams sodium chloride or less than 2.3 grams sodium per day) is recommended. With appropriate counseling, this is an achievable diet. Blood pressure may be controlled by this degree of sodium chloride restriction in some patients with Stage 1 hypertension; in those patients who still need drug therapy, the medication requirements may be decreased.

Potassium

A high dietary potassium intake may protect against developing hypertension,⁴¹ and potassium deficiency may increase blood pressure and induce ventricular ectopy.⁴⁹ Therefore, normal plasma concentrations of potassium should be maintained, preferably from food sources. If hypokalemia occurs during diuretic therapy, additional potassium may be needed either from potassium-containing salt substitutes, potassium supplements, or use of a potassium-sparing diuretic. Potassium chloride supplements and potassium-sparing diuretics must be used with caution in patients susceptible to hyperkalemia.

Calcium

In many but not all epidemiologic studies, there is an inverse association between dietary calcium and blood pressure. Calcium deficiency is associated with an increased prevalence of hypertension, and a low calcium intake may amplify the effects of a high sodium intake on blood

- ♦ pressure.⁵⁰ An increased calcium intake may lower blood pressure in some patients with hypertension; but the overall effect is minimal, and there is no way to predict which patients will benefit.⁵¹
- ♦ Therefore, there is currently no rationale for recommending calcium intakes in excess of the recommended daily allowance of 20 to 30 mmol (800 to 1,200 mg) in an attempt to lower blood pressure.

♦ Magnesium

- ♦ There is suggestive evidence of an association between lower dietary magnesium intake and higher blood pressures. However, there are currently no convincing data to justify recommending an increased magnesium intake in an effort to lower blood pressure.

♦ Other Dietary Factors

- ♦ **Dietary fats.** In randomized controlled studies, diets varying in total fat and proportions of saturated to unsaturated fats have had little, if any, effect on blood pressure.⁵² Although large amounts of omega-3 fatty acids may lower blood pressure,⁵³ they may be associated with

multiple adverse effects and are not recommended for treatment or prevention of high blood pressure. Nevertheless, dyslipidemia is a major independent risk factor for coronary artery disease; therefore, dietary and, if necessary, drug therapy for dyslipidemia is an important adjunct to the antihypertensive regimen.

Caffeine. Caffeine may acutely raise the blood pressure, but tolerance to this pressor effect rapidly develops. Therefore, unless cardiac or other forms of excessive sensitivity to caffeine are present, no limitation of consumption of caffeine-containing beverages is needed.

Dietary carbohydrates and protein. No consistent effects on blood pressure have been demonstrated in controlled trials of varying proportions of carbohydrate or protein in the diet.

Garlic or onion. No effects on blood pressure of increased amounts of garlic or onion have been found in controlled trials.

Relaxation and Biofeedback

Stress can raise blood pressure acutely and may contribute to the cause of hypertension, but the role of stress management techniques in treating patients with elevated blood pressure is uncertain. Relaxation therapies and biofeedback have been studied in short-term and long-term controlled trials with little effect beyond that seen in the control groups. Therefore, although stress management is an appealing concept, the available literature does not support the use of relaxation therapies for definitive therapy or prevention of hypertension.^{4,54}

Summary

Table 6 summarizes those lifestyle modifications useful in managing hypertensive

TABLE 6. LIFESTYLE MODIFICATIONS FOR HYPERTENSION CONTROL AND/OR OVERALL CARDIOVASCULAR RISK

Lose weight if overweight.

Limit alcohol intake to no more than 1 ounce of ethanol per day (24 ounces of beer, 8 ounces of wine, or 2 ounces of 100 proof whiskey).

Exercise (aerobic) regularly.

Reduce sodium intake to less than 100 mmol per day (<2.3 grams of sodium or <6 grams of sodium chloride).

Maintain adequate dietary potassium, calcium, and magnesium intake.

Stop smoking and reduce dietary saturated fat and cholesterol intake for overall cardiovascular health. Reducing fat intake also helps reduce caloric intake—important for control of weight and Type II diabetes.

patients. The modifications also may be useful in preventing blood pressures from rising and protecting cardiovascular health in those with high normal blood pressures.

PHARMACOLOGIC TREATMENT

The decision to initiate pharmacologic treatment in individual patients requires consideration of several factors: severity of blood pressure elevation, TOD, and presence of other conditions and risk factors.

Efficacy

Reducing blood pressure with drugs clearly decreases the incidence of cardiovascular mortality and morbidity.^{55,56} Protection has been demonstrated for stroke, coronary events, congestive heart failure, progression to more severe hypertension, and all-cause mortality. Meta-analysis of 14 randomized trials has indicated a 42 percent reduction in stroke from a 5 to 6 mm Hg lowering of DBP.⁵⁵ This reduction in stroke rate was highly consistent with long-term observational studies that predicted 35 to 40 percent reductions with this blood pressure difference. The same long-term analyses predicted a 20 to 25 percent reduction in the rate of CHD; however, the observed reduction from the 14 pooled trial results was 14 percent during periods of 4 to 6 years. Several explanations but little conclusive evidence have been presented to account for the less than expected reduction in CHD events in these trials.⁵⁵ This meta-analysis did not include new data from three recent clinical trials on hypertension control in older persons. The Systolic Hypertension in the Elderly Program (SHEP),⁵⁷ the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension),⁵⁸

and the Medical Research Council (MRC) Trial,⁵⁹ demonstrated a 27 percent, 13 percent, and 19 percent reduction of CHD events, respectively.

Stage 1 and Stage 2 Hypertension

If blood pressure remains at or above 140/90 mm Hg during a 3- to 6-month period despite vigorous encouragement of lifestyle modifications, antihypertensive medications should be started, especially in individuals with TOD and/or other known risk factors for CVD. In the absence of TOD and other major risk factors, some physicians may elect to withhold antihypertensive drug therapy from patients with DBP in the 90 to 94 mm Hg range and SBP in the 140 to 149 mm Hg range. In these patients, careful followup is indicated at 3- to 6-month intervals because blood pressure may rise to higher levels, and cardiac and vascular changes may occur. Clinical trial data strongly suggest that antihypertensive drug therapy should be initiated before the development of TOD.⁶⁰


Initial Drug Therapy

Initial drug therapy is monotherapy for Stage 1 and Stage 2 hypertension; that is, start with a single drug. Because diuretics and beta-blockers have been shown to reduce cardiovascular morbidity and mortality in controlled clinical trials, these two classes of drugs are preferred for initial drug therapy⁶¹ (see Figure 4). The alternative drugs—calcium antagonists, angiotensin converting enzyme (ACE) inhibitors, alpha₁-receptor blockers, and the alpha-beta blocker—are equally effective in reducing blood pressure.²⁴ Although these alternative drugs have potentially important benefits, they have not been used in long-term controlled trials to demonstrate their efficacy in

Reducing blood pressure with drugs clearly decreases the incidence of cardiovascular mortality and morbidity.

Diuretics and beta-blockers have been shown to reduce cardiovascular morbidity and mortality in controlled clinical trials — these two classes of drugs are preferred for initial drug therapy.

FIGURE 4. TREATMENT ALGORITHM



* Response means achieved goal blood pressure, or patient is making considerable progress towards this goal.

reducing morbidity and mortality and therefore should be reserved for special indications or when diuretics and beta-blockers have proved unacceptable or ineffective. There is an urgent need to evaluate the effectiveness of ACE inhibitors, calcium antagonists, and alpha₁-receptor blockers in reducing long-term cardiovascular morbidity and mortality.

Other factors that should be considered in the selection of drugs are the cost of medication, metabolic and subjective side effects, and drug-drug interactions (see Chapter IV).

Supplemental antihypertensive agents such as the direct-acting smooth muscle vasodilators, the alpha₂-agonists, and the peripherally acting adrenergic neuron antagonists are not well suited for initial monotherapy. The direct-acting smooth muscle vasodilators (e.g., hydralazine, minoxidil) often induce reflex sympathetic stimulation of the cardiovascular system and fluid retention. Alpha₂-agonists and peripheral acting adrenergic antagonists produce annoying side effects in a large number of patients.

The antihypertensive drugs are listed in Table 7.

Special Considerations

Also to be considered in the selection of initial therapy are demographic characteristics, concomitant diseases that may be beneficially or adversely affected by the antihypertensive agent chosen (see Table 8), and the use of other drugs that may lead to drug interactions (see Table 9).⁶²⁻⁶⁴

❖ *Demographics.* In general, blacks are more responsive to diuretics and calcium antagonists than to beta-blockers or ACE inhibitors. Older persons with hypertension are generally responsive

to all classes of drugs. Gender has not been found to determine drug responsiveness. In any event, gender, age, or race does not provide sufficient reason to avoid any drug class, particularly if it is needed for other therapeutic benefits because efficacy differences can usually be overcome with the addition of a diuretic or another agent.

- ❖ *Concomitant diseases and therapies* (see Table 9). Antihypertensive drugs may worsen some diseases while improving others. For example, beta-blockers may worsen asthma, diabetes, and peripheral ischemia, but they may improve angina pectoris, certain cardiac dysrhythmias, and migraine headaches, and they have proven to prolong life after myocardial infarction. Selection of an antihypertensive agent that also treats a coexisting disease may simplify therapeutic regimens and reduce costs.
- ❖ *Quality of life*. Antihypertensive drugs may cause undesirable symptoms (see Table 10). For example, many of these agents may impair sexual function, centrally acting drugs may impair mental acuity, and beta-blockers may reduce exercise tolerance.
- ❖ *Physiologic and biochemical measurements*. Some clinicians have found certain physiologic and biochemical measurements (e.g., body weight, heart rate, plasma renin activity, resting electrocardiographic tracing, and hemodynamic parameters) to be helpful in choosing specific therapy.
- ❖ *Economic considerations*. The cost of therapy may be a barrier to controlling hypertension. Treatment costs include not only the price of drugs but also the expense of routine or special laboratory

tests, supplemental therapies, office visits, and time lost from work for visits to physicians' offices.

Dosage and Followup

The lowest dosage listed in Table 7 should be selected to protect the patient from adverse effects, although it may not immediately control the blood pressure. If blood pressure remains uncontrolled, the lowest dose should be given for several weeks before it is increased to the next dosage level. It must be recognized that it may take months to control hypertension adequately while avoiding adverse effects of therapy. Most antihypertensive medications can be given once or twice daily, and this should be the goal in order to improve patient adherence. Adherence improves substantially as prescribed dose frequency decreases.⁶⁵

If, after 1 to 3 months, the response to initial therapy is inadequate, the patient is not experiencing significant side effects, and adherence to therapy is adequate, three options for subsequent therapy should be considered (see Figure 4 for treatment algorithm):

- ❖ Increase the dose of the first drug to or toward maximal levels (see Table 7);
- ❖ Substitute an agent from another class;
- ❖ Add a second drug from another class.

Combining antihypertensive drugs with different modes of action will often allow smaller doses of drugs to be used to achieve control, thereby minimizing the potential for dose-dependent side effects. If a diuretic is not chosen as the first drug, it will be useful as a second step agent because its addition usually enhances the effects of other agents. If addition of a second agent produces satisfactory blood pressure control, an at-

TABLE 7. ANTIHYPERTENSIVE AGENTS

In all patients, lifestyle modifications should also be advised (see Table 6).

Type of Drug	Usual Dosage Range (Total mg/day)*	Frequency (Once/day unless otherwise noted)	Mechanisms	Comments
INITIAL ANTIHYPERTENSIVE AGENTS				
Diuretics				❖ For thiazide and loop diuretics, lower doses and dietary counseling should be used to avoid metabolic changes.
Thiazides and related agents:				
Bendroflumethiazide	2.5 - 5	twice	Decreased plasma volume and decreased extracellular fluid volume, and decreased cardiac output initially, followed by decreased total peripheral resistance with normalization of cardiac output. Chronic effects include a slight decrease in extracellular fluid volume.	❖ More effective antihyper-tensive than loop diuretics except in patients with serum creatinine ≥221 μmol/L (2.5 mg/dL). ❖ Hydrochlorothiazide or chlorthalidone is generally preferred; were used in most clinical trials.
Benzthiazide	12.5 - 50			
Chlorothiazide	125 - 500			
Chlorthalidone	12.5 - 50			
Cyclothiazide	1.0 - 2			
Hydrochlorothiazide	12.5 - 50			
Hydroflumethiazide	12.5 - 50			
Indapamide	2.5 - 5			
Methyclothiazide	2.5 - 5			
Metolazone	0.5 - 5			
Polythiazide	1.0 - 4			
Quinethazone	25.0 - 100			
Trichlormethiazide	1.0 - 4			
Loop diuretics:			See thiazides.	❖ Higher doses of loop diuretics may be needed for patients with renal impairment or congestive heart failure. ❖ Ethacrynic acid is the only alternative for patients with allergy to thiazide and sulfur-containing diuretics.
Bumetanide	0.5 - 5	twice		
Ethacrynic acid	25.0 - 100	twice		
Furosemide	20.0 - 320	twice		
Potassium sparing:			Increased potassium reabsorption.	❖ Weak diuretics.
Amiloride	5 - 10	once or twice		
Spironolactone	25 - 100	twice or thrice	Aldosterone antagonist.	❖ Used mainly in combination with other diuretics to avoid or reverse hypokalemia from other diuretics.
Triamterene	50 - 150	once or twice		
				❖ Avoid when serum creatinine ≥221 μmol/L (2.5 mg/dL).
				❖ May cause hyperkalemia, and this may be exaggerated when combined with ACE inhibitors or potassium supplements.

TABLE 7. ANTIHYPERTENSIVE AGENTS (Continued)

Type of Drug	Usual Dosage Range (Total mg/day)*	Frequency (Once/day unless otherwise noted)	Mechanisms	Comments
Adrenergic inhibitors				
<i>Beta-blockers:</i>			Decreased cardiac output and increased total peripheral resistance. Decreased plasma renin activity. Atenolol, betaxolol, bisoprolol, and metoprolol are cardioselective.	❖ Selective agents will also inhibit beta ₂ -receptors in higher doses, e.g., all may aggravate asthma.
Atenolol	25 - 100 [†]	once or twice		
Betaxolol	5 - 40			
Bisoprolol	5 - 20			
Metoprolol	50 - 200			
Metoprolol (extended release)	50 - 200			
Nadolol	20 - 240 [†]	twice		
Propranolol	40 - 240			
Propranolol (long acting)	60 - 240			
Timolol	20 - 40	twice		
<i>Beta-blockers with intrinsic sympathomimetic activity (ISA):</i>			Acebutolol is cardioselective.	❖ No clear advantage for agents with ISA except in those with bradycardia who must receive a beta-blocker; they produce fewer or no metabolic side effects.
Acebutolol	200 - 1200 [†]	twice		
Carteolol	2.5 - 10 [†]	twice		
Penbutolol	20 - 80 [†]			
Pindolol	10 - 60 [†]			
<i>Alpha-beta blocker:</i>			Same as beta-blockers plus alpha ₁ -blockade.	❖ Possibly more effective in blacks than other beta-blockers. ❖ May cause postural effects, and titration should be based on standing blood pressure.
Labetalol	200 - 1200	twice		
<i>Alpha₁-receptor blockers:</i>			Block postsynaptic alpha ₁ -receptors and cause vasodilation.	❖ All may cause postural effects, and titration should be based on standing blood pressure.
Doxazosin	1.0 - 16	twice or thrice		
Prazosin	1.0 - 20			
Terazosin	1.0 - 20			
ACE inhibitors				
Benazepril	10.0 - 40 [†]	once or twice	Block formation of angiotensin II, promoting vasodilation and decreased aldosterone. Also increased bradykinin and vasodilatory prostaglandins.	❖ Diuretic doses should be reduced or discontinued prior to starting ACE inhibitors whenever possible to prevent excessive hypotension. ❖ Reduce dose of those drugs marked "*" in patients with serum creatinine ≥221 μmol/L (2.5 mg/dL). ❖ May cause hyperkalemia in patients with renal impairment or in those receiving potassium-sparing agents ❖ Can cause acute renal failure in patients with severe bilateral renal artery stenosis or severe stenosis in an artery to a solitary kidney.
Captopril	12.5 - 150 [†]	twice		
Cilazapril	2.5 - 5.0	once or twice		
Enalapril	2.5 - 40 [†]	once or twice		
Fosinopril	10.0 - 40	once or twice		
Lisinopril	5.0 - 40 [†]	once or twice		
Perindopril	1.0 - 16 [†]	once or twice		
Quinapril	5.0 - 80 [†]	once or twice		
Ramipril	1.25 - 20 [†]	once or twice		
Spirapril	12.5 - 50	once or twice		

TABLE 7. ANTIHYPERTENSIVE AGENTS (Continued)

Type of Drug	Usual Dosage Range (Total mg/day)*	Frequency (Once/day unless otherwise noted)	Mechanisms	Comments
Calcium antagonists			Block the inward movement of calcium ion across cell membranes and cause smooth muscle relaxation.	❖ These agents also block the slow channels in the heart and may reduce sinus rate and produce heart block.
Diltiazem	90 - 360	thrice		
Diltiazem (sustained release)	120 - 360	twice		
Diltiazem (extended release)	180 - 360			
Verapamil	80 - 480	twice		
Verapamil (long acting)	120 - 480	once or twice		
Dihydropyridines				
Amlodipine	2.5 - 10			❖ Dihydropyridines are more potent peripheral vasodilators than diltiazem and verapamil and may cause more dizziness, headache, flushing, peripheral edema, and tachycardia.
Felodipine	5 - 20			
Isradipine	2.5 - 10	twice		
Nicardipine	60 - 120	thrice		
Nifedipine	30 - 120	thrice		
Nifedipine (GITS)	30 - 90			
SUPPLEMENTAL ANTIHYPERTENSIVE AGENTS				
Centrally acting alpha ₂ -agonists				
Clonidine	0.1 - 1.2	twice	Stimulate central alpha ₂ -receptors that inhibit efferent sympathetic activity.	❖ Clonidine patch is replaced once a week.
Clonidine TTS (patch)**	0.1 - 0.3	once <u>weekly</u>		
Guanabenz	4 - 64	twice		❖ None of these agents should be withdrawn abruptly. Avoid in nonadherent patients.
Guanfacine	1 - 3			
Methyldopa	250 - 2000	twice		
Peripheral acting adrenergic antagonists				
Guanadrel	10 - 75	twice	Inhibits catecholamine release from neuronal storage sites.	❖ May cause serious orthostatic and exercise-induced hypotension.
Guanethidine	10 - 100			
Rauwolfia alkaloids:				
Rauwolfia root	50 - 200		Depletion of tissue stores of catecholamines.	
Reserpine	0.05 [§] - 0.25			
Direct vasodilators				
Hydralazine	50 - 300	twice to four times	Direct smooth muscle vasodilation (primarily arteriolar).	❖ Hydralazine is subject to phenotypically determined metabolism (acetylation).
Minoxidil	2.5 - 80	once or twice		
				❖ For both agents: should treat concomitantly with a diuretic and a beta-blocker due to fluid retention and reflex tachycardia.

* The lower dose indicated is the preferred initial dose, and the higher dose is the maximum daily dose. Most agents require 2 to 4 weeks for complete efficacy, and more frequent dosage adjustments are not advised except for severe hypertension. The dosage range may differ slightly from the recommended dosage in the "Physicians' Desk Reference" or package insert.

† Indicates drugs that are excreted by the kidney and require dosage reduction in the presence of renal impairment (serum creatinine $\geq 221 \mu\text{mol/L}$ [2.5 mg/dL]).

**Weekly patch is 1, 2, 3 equivalent to 0.1 - 0.3 mg. per day.

§ 0.1 mg. dose may be given every other day to achieve this dosage.

TABLE 8. ANTIHYPERTENSIVE DRUG THERAPY: INDIVIDUALIZATION BASED ON SPECIAL CONSIDERATIONS

(Guidelines for selecting initial therapy)

Clinical Situation	Preferred	Requires Special Monitoring	Relatively or Absolutely Contraindicated
Cardiovascular:			
Angina pectoris	Beta-blockers; Calcium antagonists		Direct vasodilators
Bradycardia/Heart block, Sick sinus syndrome			Beta-blockers; Labetalol; Verapamil; Diltiazem
Cardiac failure	Diuretics; ACE inhibitors		Beta-blockers; Calcium antagonists; Labetalol
Hypertrophic cardiomyopathy with severe diastolic dysfunction	Beta-blockers; Diltiazem; Verapamil		Diuretics; ACE inhibitors; Alpha ₁ -blockers; Hydralazine; Minoxidil
Hyperdynamic circulation	Beta-blockers		Direct vasodilators
Peripheral vascular occlusive disease		Beta-blockers	
Post myocardial infarction	Non-ISA Beta-blockers		Direct vasodilators
Renal:			
Bilateral renal arterial disease or severe stenosis in artery to solitary kidney			ACE inhibitors
Renal insufficiency			
Early (serum creatinine 130 to 221 µmol/L [1.5 to 2.5 mg/dL])			Potassium-sparing agents; Potassium supplements
Advanced (serum creatinine ≥221 µmol/L [2.5 mg/dL])	Loop diuretics	ACE inhibitors	Potassium-sparing agents; Potassium supplements
Other:			
Asthma/COPD			Beta-blockers; Labetalol
Cyclosporine-associated hypertension	Nifedipine; Labetalol	Verapamil*; Diltiazem*; Nicardipine*	
Depression		Alpha ₂ -agonists	Reserpine
Diabetes mellitus			
Type I (Insulin dependent)		Beta-blockers	
Type II		Beta-blockers; Diuretics	
Dyslipidemia		Diuretics; Beta-blockers	
Liver disease		Labetalol	Methyldopa
Vascular headache	Beta-blockers		
Pregnancy			
Preeclampsia	Methyldopa; Hydralazine		Diuretics; ACE inhibitors
Chronic hypertension	Methyldopa		ACE inhibitors

*Can increase serum levels of cyclosporine.

TABLE 9. SELECTED DRUG INTERACTIONS WITH ANTIHYPERTENSIVE THERAPY*

Diuretics*Possible situations for decreased antihypertensive effects:*

- ❖ Cholestyramine and colestipol decrease absorption.
- ❖ NSAID's (including aspirin and over-the-counter ibuprofen) may antagonize diuretic effectiveness.

Possible situations for increased antihypertensive effects:

- ❖ Combinations of thiazides (especially metolazone) with furosemide can produce profound diuresis, natriuresis, and kaliuresis in renal impairment.

Effects of diuretics on other drugs:

- ❖ Diuretics can raise serum lithium levels and increase toxicity by enhancing proximal tubular reabsorption of lithium.
- ❖ Diuretics may make it more difficult to control dyslipidemia and diabetes.

Beta-blockers*Possible situations for decreased antihypertensive effects:*

- ❖ NSAID's may decrease the effects of beta-blockers.
- ❖ Rifampin, smoking, and phenobarbital decrease serum levels of agents primarily metabolized by the liver due to enzyme induction.

Possible situations for increased antihypertensive effects:

- ❖ Cimetidine may increase serum levels of beta-blockers that are primarily metabolized by the liver due to enzyme inhibition.
- ❖ Quinidine may increase the risk of hypotension.

Effects of beta-blockers on other drugs:

- ❖ Combinations of diltiazem or verapamil with beta-blockers may have additive sinoatrial (SA) and atrioventricular (AV) node depressant effects and may also promote negative inotropic effects on the failing myocardium.
- ❖ Combination of beta-blockers and reserpine may cause marked bradycardia and syncope.
- ❖ Beta-blockers may increase serum levels of theophylline, lidocaine, and chlorpromazine due to reduced hepatic clearance.
- ❖ Nonselective beta-blockers prolong insulin-induced hypoglycemia and promote rebound hypertension due to unopposed alpha stimulation. All beta-blockers mask the adrenergically mediated symptoms of hypoglycemia and have the potential to aggravate diabetes.
- ❖ Beta-blockers may make it more difficult to control dyslipidemia.

- ❖ Phenylpropanolamine (which can be obtained over the counter in cold and diet preparations), pseudoephedrine, ephedrine, and epinephrine can cause elevations in blood pressure due to unopposed alpha-receptor-induced vasoconstriction.

ACE inhibitors*Possible situations for decreased antihypertensive effects:*

- ❖ NSAID's (including aspirin and over-the-counter ibuprofen) may decrease blood pressure control.
- ❖ Antacids may decrease the bioavailability of ACE inhibitors.

Possible situations for increased antihypertensive effects:

- ❖ Diuretics may lead to excessive hypotensive effects (hypovolemia).

Effect of ACE inhibitors on others drugs:

- ❖ Hyperkalemia may occur with potassium supplements, potassium-sparing agents, and NSAID's.
- ❖ ACE inhibitors may increase serum lithium levels.

Calcium antagonists*Possible situations for decreased antihypertensive effects:*

- ❖ Serum levels and antihypertensive effects of calcium antagonists may be diminished by these interactions: rifampin-verapamil; carbamazepine-diltiazem and verapamil; phenobarbital and phenytoin-verapamil.

Possible situations for increased antihypertensive effects:

- ❖ Cimetidine may increase pharmacologic effects of all calcium antagonists due to inhibition of hepatic metabolizing enzymes resulting in increased serum levels.

Effects of calcium antagonists on other drugs:

- ❖ Digoxin and carbamazepine serum levels and toxicity may be increased by verapamil and possibly by diltiazem.
- ❖ Serum levels of prazosin, quinidine, and theophylline may be increased by verapamil.
- ❖ Serum levels of cyclosporine may be increased by diltiazem, nifedipine, and verapamil. Cyclosporine dose may need to be decreased.

Alpha-blockers*Possible situations for increased antihypertensive effects:*

- ❖ Concomitant antihypertensive drug therapy (especially diuretics) may increase chance of postural hypotension.

TABLE 9. SELECTED DRUG INTERACTIONS WITH ANTIHYPERTENSIVE THERAPY (Continued)

Sympatholytics*Possible situations for decreased antihypertensive effects:*

- ❖ Tricyclic antidepressants may decrease the effects of centrally acting and peripheral norepinephrine depleters.
- ❖ Sympathomimetics including over-the-counter cold and diet preparations, amphetamines, phenothiazines, and cocaine may interfere with the antihypertensive effects of guanethidine and guanadrel.
- ❖ The severity of clonidine withdrawal reaction can be increased by beta-blockers.

- ❖ Monoamine oxidase inhibitors may prevent degradation and metabolism of norepinephrine released by tyramine-containing foods and may cause hypertension. They may also cause hypertensive reactions when combined with reserpine or guanethidine.

Effects of sympatholytics on other drugs:

- ❖ Methyldopa may increase serum lithium levels.

* *This table does not include all potential drug interactions with antihypertensive drugs.*

tempt to withdraw the first agent may be considered because monotherapy with virtually all agents provides blood pressure control for at least half of all patients.

Before proceeding to each successive treatment step, clinicians should address possible reasons for lack of responsiveness to therapy, including those listed in Table 11.

After blood pressure is reduced to goal level and maintenance doses of antihypertensive drugs are stabilized, substituting comparable combination tablets may simplify patients' regimens and promote adherence to a comprehensive antihypertensive treatment program.

Stage 3 and Stage 4 Hypertension

Although similar general approaches are advocated for all patients with hypertension, modification may be appropriate for those with DBP of 110 mm Hg or higher and/or SBP 180 mm Hg or higher. Although some patients may respond adequately to only one drug, it is often necessary to add a second or third agent after a short interval if control is not achieved. The intervals between changes in the regimen should be decreased, and the maximum dose of some drugs may be increased. In some patients it may be

necessary to start treatment with more than one agent. Patients with average DBP of 120 mm Hg or greater require more immediate therapy and, if significant TOD is present, may require hospitalization and consultation.

Isolated Systolic Hypertension

Isolated systolic hypertension frequently occurs in older persons and is discussed in more detail in the Hypertension in the Older Patients section (see Chapter IV). When isolated systolic hypertension occurs in adolescents and young adults, it often indicates a hyperdynamic circulation and may predict future diastolic elevation. Lifestyle modifications should be used in an attempt to lower isolated systolic hypertension. However, when the SBP is consistently 160 mm Hg or greater and the DBP is less than 90 mm Hg despite lifestyle modification, antihypertensive drug treatment is indicated for older patients and should be considered for younger patients.

Step-Down Therapy

Sound patient management should include attempts to decrease the dosage or number of antihypertensive drugs while maintaining lifestyle modifications. In general, complete cessation of an

After blood pressure has been effectively controlled for 1 year and at least four visits, it may be possible to reduce antihypertensive drug therapy in a deliberate, slow, and progressive manner.

TABLE 10. ADVERSE DRUG EFFECTS

Drugs*	Selected Side Effects†	Precautions and Special Considerations
Diuretics**		
<i>Thiazides and related diuretics</i>	Hypokalemia, hypomagnesemia, hyponatremia, hyperuricemia, hypercalcemia, hyperglycemia, hypercholesterolemia, hypertriglyceridemia, sexual dysfunction, weakness	Except for metolazone and indapamide, ineffective in renal failure (serum creatinine $\geq 221 \mu\text{mol/L}$ [2.5 mg/dL]); hypokalemia increases digitalis toxicity; may precipitate acute gout.
<i>Loop diuretics</i>	Same as for thiazides except loop diuretics do not cause hypercalcemia	Effective in chronic renal failure.
<i>Potassium-sparing agents</i>	Hyperkalemia	Danger of hyperkalemia in patients with renal failure, in patients treated with an ACE inhibitor or with NSAID's.
Amiloride		
Spironolactone	Gynecomastia, mastodynia, menstrual irregularities, diminished libido in males	
Triamterene		Danger of renal calculi.
Adrenergic inhibitors		
<i>Beta-blockers**</i>	Bronchospasm, may aggravate peripheral arterial insufficiency, fatigue, insomnia, exacerbation of congestive heart failure, masking of symptoms of hypoglycemia. Also, hypertriglyceridemia, decreased high-density lipoprotein cholesterol (except for those drugs with ISA). Reduces exercise tolerance.	Should not be used in patients with asthma, chronic obstructive pulmonary disease (COPD), congestive heart failure with systolic dysfunction, heart block (greater than first degree), and sick sinus syndrome; use with caution in insulin-treated diabetics and patients with peripheral vascular disease; should not be discontinued abruptly in patients with ischemic heart disease.
<i>Alpha-beta blocker</i> Labetalol	Bronchospasm, may aggravate peripheral vascular insufficiency, orthostatic hypotension	Should not be used in patients with asthma, COPD, congestive heart failure, heart block (greater than first-degree), and sick sinus syndrome; use with caution in insulin-treated diabetics and patients with peripheral vascular disease.
<i>Alpha₁-receptor blockers</i>	Orthostatic hypotension, syncope, weakness, palpitations, headache	Use cautiously in older patients because of orthostatic hypotension.
ACE inhibitors	Cough, rash, angioneurotic edema, hyperkalemia, dysgeusia	Hyperkalemia can develop, particularly in patients with renal insufficiency; hypotension has been observed with initiation of ACE inhibitors, especially in patients with high plasma renin activity or in those receiving diuretic therapy; can cause reversible, acute renal failure in patients with bilateral renal arterial stenosis or unilateral stenosis in a solitary kidney and in patients with cardiac failure and with volume depletion; rarely can induce neutropenia or proteinuria; absolutely contraindicated in second and third trimesters of pregnancy.

TABLE 10. ADVERSE DRUG EFFECTS (Continued)

Drugs*	Selected Side Effects†	Precautions and Special Considerations
Calcium antagonists		
Dihydropyridines Amlodipine Felodipine Isradipine Nicardipine Nifedipine	Headache, dizziness, peripheral edema, tachycardia, gingival hyperplasia	Use with caution in patients with congestive heart failure; may aggravate angina and myocardial ischemia.
Diltiazem Verapamil	Headache, dizziness, peripheral edema, (less common than with dihydropyridines), gingival hyperplasia, constipation (especially verapamil), atrioventricular block, bradycardia	Use with caution in patients with cardiac failure; contraindicated in patients with second- or third-degree heart block, or sick sinus syndrome.
Centrally acting α_2-agonists		
Clonidine Guanabenz Guanfacine hydrochloride	Drowsiness, sedation, dry mouth, fatigue, orthostatic dizziness	Rebound hypertension may occur with abrupt discontinuance, particularly with prior administration of high doses or with continuation of concomitant beta-blocker therapy.
Clonidine TTS (patch)	Same as for clonidine; localized skin reaction to the patch	
Methyldopa		May cause liver damage, fever, and Coombs-positive hemolytic anemia.
Peripheral acting adrenergic antagonists		
Guanadrel sulfate Guanethidine monosulfate	Diarrhea, orthostatic and exercise hypotension	Use cautiously because of orthostatic hypotension.
Rauwolfia alkaloids Reserpine	Lethargy, nasal congestion, depression	Contraindicated in patients with history of mental depression or with active peptic ulcer.
Direct vasodilators		
	Headache, tachycardia, fluid retention	May precipitate angina pectoris in patients with coronary artery disease; generally, use with diuretic and beta-blocker.
Hydralazine	Positive antinuclear antibody test	Lupus syndrome may occur (rare at recommended doses).
Minoxidil	Hypertrichosis	May cause or aggravate pleural and pericardial effusions.

* See Table 7 for a list of drugs.

† The listing of side effects is not all-inclusive, and clinicians are urged to refer to the package insert for a more detailed listing. Sexual dysfunction, particularly impotence in men, has been reported with the use of all antihypertensive agents. Few data are available on the effect of antihypertensive agents on sexual function in women.

** Some of the metabolic side effects of diuretics and beta-blockers can be minimized by appropriate dietary counseling.

TABLE 11. CAUSES FOR LACK OF RESPONSIVENESS TO THERAPY

Nonadherence to therapy

- ❖ Cost of medication
- ❖ Instructions not clear and/or not given to the patient in writing
- ❖ Inadequate or no patient education
- ❖ Lack of involvement of the patient in the treatment plan
- ❖ Side effects of medication
- ❖ Organic brain syndrome (e.g., memory deficit)
- ❖ Inconvenient dosing

Drug-related causes

- ❖ Doses too low
- ❖ Inappropriate combinations (e.g., two centrally acting adrenergic inhibitors)
- ❖ Rapid inactivation (e.g., hydralazine)
- ❖ Drug interactions
 - Nonsteroidal anti-inflammatory drugs
 - Oral contraceptives
 - Sympathomimetics
 - Antidepressants
 - Adrenal steroids
 - Nasal decongestants
 - Licorice-containing substances (e.g., chewing tobacco)
 - Cocaine
 - Cyclosporine
 - Erythropoietin

Associated conditions

- ❖ Increasing obesity
- ❖ Alcohol intake more than 1 ounce of ethanol a day

Secondary hypertension

- ❖ Renal insufficiency
- ❖ Renovascular hypertension
- ❖ Pheochromocytoma
- ❖ Primary aldosteronism

Volume overload

- ❖ Inadequate diuretic therapy
- ❖ Excess sodium intake
- ❖ Fluid retention from reduction of blood pressure
- ❖ Progressive renal damage

Pseudohypertension

antihypertensive treatment program is not indicated. However, after blood pressure has been effectively controlled for 1 year and at least four visits, it may be possible to reduce antihypertensive drug therapy in a deliberate, slow, and progressive manner. Step-down therapy is especially successful in patients who are also following lifestyle treatment recommendations: a higher percentage maintain normal blood pressure levels with less or no medication.²⁸ Patients whose drugs have been discontinued should have regular followup because blood pressure usually rises again to hypertensive levels, sometimes months or years after discontinuance, especially in the absence of sustained improvements in lifestyle.

J-Curve Hypothesis

Concerns have been raised that lowering DBP too much may increase risk for coronary disease possibly by lowering diastolic perfusion pressure in the coronary circulation—the so-called “J-curve” hypothesis.^{23,66} This concern may be more relevant to hypertensive patients with preexisting coronary disease. No data support a similar relationship of blood pressure reduction to adverse effects on cerebral or renal function. Regardless of the presence or absence of a J-curve, available evidence supports the reduction of diastolic and systolic blood pressure at all ages to the levels achieved in clinical trials—usually less than 90 mm Hg DBP, and 140-160 mm Hg in isolated systolic hypertension.

Resistant Hypertension

Hypertension should be considered resistant if the blood pressure in an adherent patient cannot be reduced to less than 160/100 mm Hg by an adequate and appropriate triple-drug regimen prescribed

in nearly maximal doses when the pretreatment blood pressure was greater than 180/115 mm Hg. If the pretreatment blood pressure was less than 180/115 mm Hg, resistance should be defined as failure to achieve normotension (less than 140/90 mm Hg) on a similar regimen. An adequate and appropriate regimen should include at least three different pharmacologic agents, including a diuretic plus two of the following classes of drugs: beta-adrenergic blocker or another antiadrenergic agent, direct vasodilator, calcium antagonist, or ACE inhibitor.

For older patients with isolated systolic hypertension, resistance in an adherent patient is defined as failure of an adequate triple-drug regimen to reduce systolic blood pressure to less than 170 mm Hg if pretreatment systolic pressure was greater than 200 mm Hg or to less than 160 mm Hg and by at least 10 mm Hg if pretreatment systolic blood pressure was 160 to 200 mm Hg.

If goal blood pressure cannot be achieved without intolerable side effects, even suboptimal reduction of blood pressure will contribute to decreased morbidity and mortality.

Hypertensive Crises: Emergencies and Urgencies

Hypertensive emergencies are those situations that require immediate blood pressure reduction (not necessarily to normal ranges) to prevent or limit target-organ disease. Examples include hypertensive encephalopathy, intracranial hemorrhage, acute left ventricular failure with pulmonary edema, dissecting aortic aneurysm, eclampsia or severe hypertension associated with pregnancy, unstable angina pectoris, and acute myocardial infarction. Hypertensive urgencies are those situa-

tions in which it is desirable to reduce blood pressure within 24 hours. Hypertensive urgencies include accelerated or malignant hypertension without severe symptoms or progressive target-organ complications and severe perioperative hypertension. Drugs available and their routes of administration are listed in Table 12.⁶⁷

Although most hypertensive emergencies are treated initially with parenteral administration of an appropriate agent, oral administration of selected agents may also be associated with rapid reduction in blood pressure. There is no clearly defined clinical advantage for sublingual over oral administration of nifedipine or captopril.

When treating the hypertensive urgency or emergency, it is desirable to choose agents that enable a controlled reduction in blood pressure over 30 minutes to several hours. Elevated blood pressure alone, in the absence of symptoms or evident target-organ disease, rarely requires emergency therapy. The risks of overly aggressive intervention in any hypertensive crisis must always be considered. Even the administration of oral agents for hypertensive urgencies has resulted in myocardial ischemia and cerebral hypoperfusion.

LONG-TERM ADHERENCE TO THERAPY

Followup Visits

Achieving and maintaining target blood pressure with the lowest possible dosage of medication requires ongoing patient followup and may involve dosage adjustments. Patients with Stage 1 hypertension without TOD should generally be seen within 1 to 2 months following the initiation of therapy to determine the adequacy of blood pressure control, the

TABLE 12. MANAGEMENT OF THE HYPERTENSIVE CRISIS: EMERGENCIES AND URGENCIES

	Dose	Onset	Cautions
Parenteral vasodilators			
Sodium nitroprusside	0.25-10 µg/kg/min as IV infusion Maximal dose for 10 minutes only	Instantaneous	Nausea, vomiting, muscle twitching; with prolonged use may cause thiocyanate intoxication, methemoglobinemia acidosis, cyanide poisoning; bags, bottles, and delivery sets must be light resistant.
Nitroglycerin	5-100 µg/min as IV infusion	2-5 min	Headache, tachycardia, vomiting, flushing, methemoglobinemia; requires special delivery system due to drug binding to PVC tubing.
Diazoxide	50-150 mg IV bolus, repeated, or 15-30 mg/min by IV infusion	1-2 min	Hypotension, tachycardia, aggravation of angina pectoris, nausea and vomiting, hyperglycemia with repeated injections.
Hydralazine	10-20 mg IV bolus 10-40 mg IM	10 min 20-30 min	Tachycardia, headache, vomiting, aggravation of angina pectoris.
Enalaprilat	0.625-1.25 mg every 6 hours IV	15-60 min	Renal failure in patients with bilateral renal artery stenosis, hypotension.
Parenteral adrenergic inhibitors			
Phentolamine	5-15 mg IV bolus	1-2 min	Tachycardia, orthostatic hypotension.
Trimethaphan camsylate	1-4 mg/min as IV infusion	1-5 min	Paresis of bowel and bladder, orthostatic hypotension, blurred vision, dry mouth.
Labetalol	20-80 mg IV bolus every 10 min; 2 mg/min IV infusion	5-10 min	Bronchoconstriction, heart block, orthostatic hypotension.
Methyldopate	250-500 mg IV infusion every 6 hours	30-60 min	Drowsiness.
Oral agents			
Nifedipine (not extended release)	10-20 mg PO, repeat after 30 minutes	15-30 min	Rapid, uncontrolled reduction in blood pressure may precipitate circulatory collapse in patients with aortic stenosis.
Captopril	25 mg PO, repeat as required	15-30 min	Hypotension, renal failure in bilateral renal artery stenosis.
Clonidine	0.1-0.2 mg PO, repeated every hour as required to a total dose of 0.6 mg	30-60 min	Hypotension, drowsiness, dry mouth.
Labetalol	200-400 mg PO, repeat every 2-3 hours	30 min-2 hours	Bronchoconstriction, heart block, orthostatic hypotension.

Note: It is sometimes appropriate to administer a diuretic agent with any of the above.

degree of patient adherence, and the presence of adverse effects. Associated medical problems, including TOD, other major risk factors, and laboratory test abnormalities will also play a part in determining the frequency of patient followup. Once stabilized, followup at 3- to 6-month intervals (depending on the patient's status) is generally appropriate. Monitoring should include blood pressure measurements in the supine or sitting positions and after standing quietly for 2 minutes. Patient education should be an important feature of followup visits.

Planned Patient Education Programs

Poor adherence to long-term treatment, both lifestyle modifications and pharmacologic therapy, has been identified as the major reason for inadequate control of high blood pressure. Planned patient education programs may significantly improve adherence to treatment schedules, improve blood pressure control, and decrease hypertension-related morbidity and mortality.⁶⁸ Combinations of patient education intervention strategies are likely to achieve the greatest improvement in

long-term adherence and are usually aimed at improving patient understanding of specific therapies and treatment goals, correcting misconceptions, adjusting the therapeutic interventions to patients' lifestyles, and enhancing family or other social support.

Strategies To Improve Adherence to Therapy and Control of High Blood Pressure

The choice and application of specific strategies will depend on individual patient characteristics, severity of specific diseases, and co-morbidities. It is not expected that all strategies would be applied any one time, nor to all patients, as prioritization should occur on an individual basis. It is recommended to review patient progress and effectiveness of the approaches at followup visits. Over time, the patient's needs may change and behavioral and pharmacological approaches may need to be altered. Table 13 outlines a series of strategies to enhance adherence to treatment. They are designed to provide guidance at the initial, as well as followup visits.

Planned patient education programs may significantly improve adherence to treatment schedules.

TABLE 13. PREVENTING, MONITORING, AND ADDRESSING PROBLEMS OF ADHERENCE
Educate about conditions and treatment:

- ❖ Assess patient's understanding and acceptance of the diagnosis and expectations of being in care;
- ❖ Discuss patient's concerns and clarify misunderstandings;
- ❖ Inform patient of blood pressure level;
- ❖ Agree with patient on a goal blood pressure;
- ❖ Inform patient about recommended treatment and provide specific written information;
- ❖ Elicit concerns and questions and provide opportunities for patient to state specific behaviors to carry out treatment recommendations;
- ❖ Emphasize need to continue treatment, that patient cannot tell if blood pressure is elevated, and that control does not mean cure.

Individualize the regimen:

- ❖ Include patient in decision making;
- ❖ Simplify the regimen;
- ❖ Incorporate treatment into patient's daily lifestyle;
- ❖ Set, with the patient, realistic short-term objectives for specific components of the treatment plan;
- ❖ Encourage discussion of side effects and concerns;
- ❖ Encourage self-monitoring;
- ❖ Minimize cost of therapy;
- ❖ Indicate you will ask about adherence at next visit;
- ❖ When weight loss is established as a treatment goal, discourage quick weight loss regimens, fasting or unscientific methods, since these are associated with weight cycling which may increase cardiovascular morbidity and mortality.

Provide reinforcement:

- ❖ Provide feedback regarding blood pressure level;
- ❖ Ask about behaviors to achieve blood pressure control;
- ❖ Give positive feedback for behavioral and blood pressure improvement;
- ❖ Hold exit interviews to clarify regimen;
- ❖ Make appointment for next visit before patient leaves the office;
- ❖ Use appointment reminders and contact patients to confirm appointments;
- ❖ Schedule more frequent visits to counsel non-adherent patients;
- ❖ Contact and follow up patients who missed appointments;
- ❖ Consider clinician-patient contracts.

Promote social support:

- ❖ Educate family members to be part of the blood pressure control process and provide daily reinforcement;
- ❖ Suggest small group activities to enhance mutual support and motivation.

Collaborate with other professionals:

- ❖ Draw upon complementary skills and knowledge of nurses, pharmacists, dietitians, optometrists, dentists, and physician assistants;
 - ❖ Refer patients for more intensive counseling.
-

CHAPTER IV

SPECIAL POPULATIONS AND SITUATIONS

HYPERTENSION IN AFRICAN AMERICANS AND OTHER RACIAL AND ETHNIC MINORITIES

The frequency of hypertension in African Americans is among the highest in the world,⁴¹ and hypertension is the major health problem of adult African Americans. Blacks develop hypertension at an earlier age; and, at any decade of life, hypertension is more severe in blacks than in whites. As much as 30 percent of all deaths in hypertensive black men and 20 percent of all deaths in hypertensive black women may be attributable to high blood pressure.⁶⁹ This earlier onset, higher prevalence, and greater severity of hypertension in blacks than in whites is accompanied by a 1.3-fold greater rate of nonfatal stroke, a 1.8-fold greater rate of fatal stroke, a 1.5-fold greater rate of heart disease deaths,⁷⁰ and a 5-fold greater rate of end-stage renal disease.⁷¹

Available evidence indicates that at similar starting blood pressure levels, blacks, when provided equal access to adequate therapy, will achieve similar overall blood pressure declines and may experience a lower incidence of CVD than whites.⁷²

Because of the high prevalence of salt sensitivity, obesity, and cigarette smoking in blacks, lifestyle modifications are particularly important. The control of obesity is of particular importance because blacks have twice the prevalence of non-insulin-dependent diabetes mellitus.

In blacks, diuretics have been proven in controlled trials to reduce hypertensive morbidity and mortality; thus, diuretics should be the agent of first choice in the absence of other conditions that prohibit their use. Monotherapy with beta-blockers or ACE inhibitors is less effective in blacks; but calcium antagonists, alpha₁-receptor blockers, and the alpha-beta blocker are as effective in blacks as in whites. Because of the greater rate of severe hypertension in blacks, more black patients will require multidrug therapy, and clinicians should not hesitate to use the most powerful agents, including minoxidil, especially in those with impaired renal function.

Little information is available on whether other racial and ethnic groups—including Native Americans, Asians and Pacific Islanders, and Hispanics—respond differently from whites to antihypertensive medications or lifestyle modifications. Further studies are needed to better understand the factors influencing the control of hypertension in these groups.

HYPERTENSION IN CHILDREN

According to the “Report of the Second Task Force on Blood Pressure Control in Children,”⁷³ hypertension in children is

*Blacks, when
provided equal
access to
adequate therapy,
will achieve
similar overall
blood pressure
declines.*

- ♦ defined as average systolic and/or diastolic blood pressure equal to or greater than the 95th percentile for age on at least three occasions (see Table 14). In many of the childhood cases, significant and severe hypertension may have an identifiable underlying cause. Children who have slight or periodic blood pressure elevation frequently exhibit other risk factors for future CVD that usually persist into adult life and often cluster within families. All clinicians who care for children age 3 through adolescence should be encouraged to measure blood pressure once a year, when the child is well.⁷³ This is especially true in children who have a hypertensive parent. Likewise, the parents of children who exhibit elevated pressures should also be screened.

TABLE 14. CLASSIFICATION OF HYPERTENSION IN THE YOUNG BY AGE GROUP*

	High Normal 90-94th Percentile (mm Hg)	Significant Hypertension 95-99th Percentile (mm Hg)	Severe Hypertension > 99th Percentile (mm Hg)
Newborns			
7 days		SBP 96-105	SBP ≥ 106
8-30 days		SBP 104-109	SBP ≥ 110
Infants (≤2 years)	SBP 104-111 DBP 70-73	SBP 112-117 DBP 74-81	SBP ≥ 118 DBP ≥ 82
Children (3-5 years)	SBP 108-115 DBP 70-75	SBP 116-123 DBP 76-83	SBP ≥ 124 DBP ≥ 84
Children (6-9 years)	SBP 114-121 DBP 74-77	SBP 122-129 DBP 78-85	SBP ≥ 130 DBP ≥ 86
Children (10-12 years)	SBP 122-125 DBP 78-81	SBP 126-133 DBP 82-89	SBP ≥ 134 DBP ≥ 90
Children (13-15 years)	SBP 130-135 DBP 80-85	SBP 136-143 DBP 86-91	SBP ≥ 144 DBP ≥ 92
Adolescents (16-18 years)	SBP 136-141 DBP 84-91	SBP 142-149 DBP 92-97	SBP ≥ 150 DBP ≥ 98

* This classification table is adapted from the "Report of the Second Task Force on Blood Pressure Control in Children—1987."⁷³ Note that adult classifications differ.

The "Report of the Second Task Force on Blood Pressure Control in Children"⁷³ offers a comprehensive approach to the detection, evaluation, and treatment of high blood pressure in children. This report provides normative data on blood pressure from more than 70,000 white, black, and Mexican-American children. Table 14 depicts the levels of blood pressure in childhood that have been used to diagnose hypertension. These levels are different from those levels found in adults because percentile levels are used in classification of blood pressure levels in children and adolescents.

Children, like adults, require repeated measurements with proper equipment to determine the level of blood pressure accurately. The widest cuff that will comfortably encircle the arm without covering the antecubital fossa should be used. For infants in whom the accuracy of measurements by auscultation is uncertain, an electronic device using a Doppler technique can be used.

The higher the blood pressure and the younger the child, the greater the possibility of secondary hypertension. Attention should also be given to risk factor assessment including family history, obesity, diet, and physical activity. In adolescents, use of alcohol, cocaine, or other addictive substances should be considered as a possible cause of the elevated blood pressure. Laboratory tests for young patients are generally similar to those recommended for adults. However, efforts to arrive at a diagnosis of secondary hypertension should be more thorough in a child.

The underlying cause, severity, or complications of hypertension in children will determine the degree and types of intervention required. Therapy should

reduce blood pressure without causing adverse effects that limit adherence or impair normal growth and development. Lifestyle modifications can be introduced as initial treatments, but may be insufficient therapy when there is severe hypertension or when there is a demonstrated cause. Weight reduction in obese children often lowers blood pressure. Antihypertensive drug therapy should usually be reserved for patients with levels of blood pressure above the 99th percentile or with significantly elevated blood pressure that responds inadequately to lifestyle modifications or is associated with TOD. As with adults, children with insulin-dependent diabetes mellitus and with primary renal disease may benefit from pharmacologic antihypertensive therapy at any level of hypertension in order to prevent or delay progression of renal insufficiency. Pharmacologic agents generally used for adults are also effective in young persons.

Uncomplicated elevated blood pressure, by itself, should not be a reason to restrict asymptomatic children from participating in physical activities, particularly because exercise may both prevent and relieve hypertension. Use of steroid hormones for the purpose of body building should be strongly discouraged.

HYPERTENSION IN WOMEN

The long-term and large clinical trials of antihypertensive treatment have included both men and women but have not clearly demonstrated gender differences in blood pressure response and outcomes.⁷⁴ Because the rate of cardiovascular events in middle-aged women is much lower than in men, these trials had limited ability to distinguish the degree of benefit from treatments between men and women.⁷⁵ Recent trials in older persons reinforce the

conclusion to support a similar approach to the management of hypertension in men and women. Therefore, at this time there are insufficient data to support a different approach to the management of hypertension in women, but further study is warranted.

Hypertension Associated With Oral Contraceptives

Most women taking oral contraceptives experience a small but detectable increase in both SBP and DBP, usually within the normal range.⁷⁶ Hypertension has been reported to be two to three times more common in women taking oral contraceptive pills for 5 years or longer than in those not taking oral contraceptives.⁷⁷ The risk appears to increase with age, with duration of use, and perhaps with increased body mass. Women age 35 and older who smoke cigarettes should be strongly counseled to stop smoking. If they continue to smoke, they should be discouraged from using oral contraceptives because most of the cardiovascular deaths attributable to oral contraceptive use have been in such women. Since many of the studies of blood pressure and oral contraceptives involved higher doses of both estrogen and progesterone than are presently in use, the current incidence of oral-contraceptive-induced hypertension is probably less than reported earlier. Nonetheless, in a small number of patients, oral contraceptives may cause accelerated or malignant hypertension.⁷⁸

The mechanism of the increase in blood pressure remains unclear. If hypertension develops in a woman taking oral contraceptives, it is advisable to stop the pill. The blood pressure will normalize in most cases within a few months. If it persists and the risks of pregnancy are

- ♦ considered to be greater than the risks of
- ♦ Stage 1 hypertension, and other contraceptive methods are not suitable, it may
- ♦ be necessary to continue the pill in spite of the elevation in blood pressure. Life-
- ♦ style modifications and antihypertensive medication should be used to
- ♦ normalize blood pressure, and patients should be carefully monitored.

♦ Hypertension in Pregnancy

- ♦ Hypertension during pregnancy may result in life-threatening consequences for
- ♦ both mother and fetus. The "NHBPEP Working Group Report on High Blood
- ♦ Pressure in Pregnancy"⁷⁹ recommends a simple classification of four diagnostic
- ♦ categories: (1) chronic hypertension, (2) preeclampsia-eclampsia, (3) chronic
- ♦ hypertension with superimposed preeclampsia, or (4) transient hypertension.
- ♦ The report emphasizes the importance of differentiating hypertension that ante-
- ♦ dates pregnancy from a pregnancy-specific condition that is characterized by
- ♦ poor perfusion of many organs and usually has increased blood pressure as one
- ♦ of its features. In the former condition, elevated blood pressure is the cardinal
- ♦ pathophysiologic feature, whereas in the latter, increased blood pressure is important
- ♦ primarily as a sign of the underlying disorder.

- ♦ **Criteria.** The criteria for diagnosing hypertension in pregnancy are SBP increases
- ♦ of 30 mm Hg or greater and DBP increases (Korotkoff phase V) of 15 mm Hg or
- ♦ greater compared with the average of values prior to 20 weeks gestation. When
- ♦ prior blood pressures are not known, a reading of 140/90 mm Hg or above is
- ♦ considered abnormal.

- ♦ **Chronic Hypertension.** Chronic hypertension is hypertension that is present

and observable before pregnancy or that is diagnosed before the 20th week of gestation. The goal of treatment of chronic hypertension in pregnancy is to minimize the short-term risks to the mother of elevated blood pressure while avoiding therapy that compromises fetal well-being. Diuretics or any other antihypertensive drugs except ACE inhibitors may be continued if taken prior to pregnancy. ACE inhibitors should be avoided because serious neonatal problems, including renal failure and death, have been reported when mothers have taken these agents during the last two trimesters.⁸⁰ For women who were not on antihypertensive therapy when they became pregnant or those whose antihypertensive therapy was increased rest or stopping work may be helpful when DBP is between 90 and 100 mm Hg. Moderate sodium restriction should only be considered if it was useful prior to pregnancy. Antihypertensive drug therapy is reserved for patients with DBP greater than or equal to 100 mm Hg.⁷⁹ Aggressive antihypertensive therapy is discouraged because of the concern for maintaining adequate uteroplacental blood flow.

Methyldopa has been most extensively evaluated in pregnancy and is therefore recommended.⁸¹ Beta-blockers compare favorably with methyldopa with respect to efficacy and are considered safe in the latter part of pregnancy, but their use early in pregnancy may be associated with growth retardation of the fetus.⁸²

Preeclampsia. The pregnancy-specific condition, preeclampsia, is increased blood pressure accompanied by proteinuria, edema or both, and at times, abnormalities of coagulation and liver function. Preeclampsia may progress rapidly to a convulsive phase, eclampsia.

Preeclampsia occurs primarily in primigravidas and after the 20th week of gestation.

Therapy for preeclampsia consists of hospitalization with bed rest, control of blood pressure, seizure prophylaxis when signs of impending eclampsia are present, and timely delivery. If preeclampsia develops before the fetus is mature, then the physician must carefully consider both the maternal and fetal health, and decide whether postponement of delivery is safe. Delivery is indicated, regardless of gestational age, when there are signs of fetal distress, uncontrollable hypertension in the mother, evidence of deteriorating renal or hepatic function, epigastric pain, or signs of impending eclampsia (e.g., headache, visual disturbance, and hyperreflexia).

The decision to use antihypertensive drugs should be based on maternal safety because there is no clear-cut fetal benefit of lowering blood pressure, and such treatment does not cure or reverse preeclampsia. Although there is disagreement regarding what level of blood pressure should be treated, most authorities would begin therapy when DBP is greater than or equal to 100 mm Hg.⁷⁹ If delivery is not anticipated in 24 hours, an oral agent is preferable, and methyldopa is the drug of choice.⁸¹ Hydralazine, calcium antagonists, alpha-beta blockers, or beta-blockers are reasonable additions or alternatives.

When delivery is imminent, a parenteral antihypertensive agent is preferable. Intravenous hydralazine is effective and has been used safely in pregnancy.⁸³ Limited data are available on the use of diazoxide, labetalol, and clonidine. Potent diuretics such as furosemide are generally not advisable.

Encouraging preliminary data involving 13 small trials suggest that low-dose aspi-

rin may prevent preeclampsia by reversing the imbalance between prostacyclin and thromboxane that may be responsible for some of the manifestations of this disease.⁸⁴ While recommendations for the general pregnant population are not warranted, low-dose aspirin (approximately 60 mg) may be useful in high risk patients, e.g., patients whose previous pregnancies were complicated by preeclampsia of early onset, those who may be at risk for recurrent fetal death or severe fetal growth retardation due to placental insufficiency, or those with poor obstetrical histories.

Estrogen Replacement Therapy and Blood Pressure

The presence of hypertension is not a contraindication to postmenopausal estrogen replacement therapy; and, in fact, such treatment may have a beneficial effect on blood pressure as well as on overall cardiovascular risk.⁸⁵ However, because a few women may experience a rise in blood pressure attributable to estrogen therapy, it is recommended that all women treated with hormonal replacement have their blood pressures monitored more frequently after such therapy is instituted. The effects of transdermal estrogen and of progestogen in addition to estrogen replacement on blood pressure in postmenopausal women have not been documented.

The presence of hypertension is not a contraindication to postmenopausal estrogen replacement therapy.

HYPERTENSION IN OLDER PATIENTS

Hypertension is present in approximately 60 percent of non-Hispanic whites, 71 percent of non-Hispanic blacks, and 61 percent of Mexican Americans 60 years or older (NHANES III). Systolic hypertension is a well-established independent risk factor for CHD, stroke, and CVD. The prevalence

The value of treating hypertension in older patients has now been established.

- ♦ of isolated systolic hypertension (ISH) (defined as SBP of 140 mm Hg or greater with a DBP less than 90 mm Hg) increases
- ♦ after age 60.
- ♦ In older patients, the sudden onset of hypertension suggests the presence
- ♦ of secondary hypertension, particularly occlusive atherosclerotic renovascular disease. Pseudohypertension is sometimes encountered in elderly patients who have
- ♦ such rigid brachial arteries that they cannot be compressed by the sphygmomanometer cuff, giving falsely high readings.
- ♦ This should be suspected when TOD is absent in spite of high blood pressures
- ♦ and can be confirmed when the pulseless radial artery is palpable even though the sphygmomanometer cuff is inflated to pressures high enough to occlude the brachial artery (Osler's sign).⁸⁶
- ♦ The value of treating hypertension in older patients has now been established (see Table 15). SHEP compared treatment
- ♦ with a low-dose diuretic, chlorthalidone, and, if needed, atenolol or reserpine to
- ♦

treatment with placebo in patients with baseline average SBP 160 mm Hg or greater and DBP less than 90 mm Hg. The results after an average of 4.5 years clearly favored active treatment, with 36 percent fewer fatal and nonfatal strokes and 27 percent fewer fatal and nonfatal myocardial infarctions in actively treated patients compared with placebo treated. Benefit was evident across all age, race, sex, and blood pressure subgroups, and active treatment was well tolerated. Data from other clinical trials indicate that older patients who have DBP of 90 mm Hg or greater will also benefit from antihypertensive therapy (see Table 15).

Therefore, the initial goal of therapy is to reduce the SBP to less than 160 mm Hg for those with a SBP greater than 180 mm Hg and to lower blood pressure by 20 mm Hg for those with SBP between 160 and 179 mm Hg. If this is well tolerated, it may be appropriate to reduce the blood pressure even further. At ISH levels of 140 to 160 mm Hg, lifestyle modifications may be

TABLE 15. EFFECTS OF THERAPY IN OLDER HYPERTENSIVE PATIENTS

Clinical trial name	Australian ⁸⁷	EWPHE ⁸⁸	Coope & Warrender ⁸⁹	STOP-Hypertension ⁵⁸	MRC ⁵⁹	SHEP ⁵⁷	HDFP ^{90*}
Number of patients	582	840	884	1,627	4,396	4,736	2,374
Age range (years)	60-69	>60	60-79	70-84	65-74	60-≥80	60-69
Mean BP at entry, mm Hg	165/101	182/101	197/100	195/102	185/91	170/77	170/101
Relative Risk of Event (treated versus control)							
Stroke	.67	.64	.58 [†]	.53 [†]	.75 [†]	.67 [†]	.56 [†]
CAD	.82	.80	1.03	.87**	.81	.73 [†]	.85 [†]
CHF	--	.78	.68	.49 [†]	--	.45 [†]	--
All CVD	.69	.71 [†]	.76 [†]	.60 [†]	.83 [†]	.68 [†]	.84 [†]

* Includes data calculated by the HDFP Coordinating Center.

† Statistically significant.

** Myocardial infarction only; sudden deaths decreased from 13 to 4.

adjunctive or definitive therapy. In general, goals of therapy for DBP in older persons are similar to those for the general population.

Antihypertensive drug therapy should be carried out more cautiously in older patients. Older patients may be more sensitive to volume depletion and sympathetic inhibition than are younger individuals because older individuals may have impaired cardiovascular reflexes that make them more susceptible to hypotension. For this reason, blood pressure should always be measured in the standing as well as seated (or supine) positions, and antihypertensive treatment should be initiated with smaller doses than usual. Increases in dosage also should be smaller and spaced at longer intervals than might be appropriate for younger patients. Drugs that have a propensity to cause orthostatic hypotension (e.g., guanethidine monosulfate, guanadrel sulfate, α_1 -receptor blockers, and labetalol) should be used with caution. All classes of antihypertensive drugs have been shown to be effective in lowering blood pressure in older patients. However, only diuretics and beta-blockers have been used in controlled trials that have shown a reduction in cardiovascular morbidity and mortality.

PATIENTS WITH HYPERTENSION AND COEXISTING CARDIOVASCULAR DISEASES

Patients With Cerebrovascular Disease

The presence of clinically evident cerebrovascular disease is an indication for antihypertensive treatment. Immediately after the occurrence of an ischemic cerebral infarction, it may be appropriate to withhold treatment (unless the blood pressure

is very high) until the situation has been stabilized. Even when treatment has been temporarily withheld, the eventual goal is to reduce blood pressure gradually with avoidance of orthostatic hypotension.

Severe hypertension that appears in the course of an acute stroke poses a difficult therapeutic problem. Some data suggest that DBP in excess of 120 mm Hg warrants cautious treatment, particularly when the hypertension is accompanied by a complication such as congestive heart failure.^{91,92}

Patients With Coronary Artery Disease

Hypertension in patients with coronary artery disease should be treated. The incidence of angina pectoris or myocardial infarction does not increase when elevated blood pressures are carefully reduced, and many patients experience a decrease in symptoms with pressure reduction. In the Multiple Risk Factor Intervention Trial (MRFIT), men with abnormal stress tests benefited substantially from risk factor reductions.^{93,94} Among MRFIT men with abnormal stress tests who were hypertensives at baseline, risk of CHD was significantly higher for usual care than for special intervention participants.⁹⁵ As with patients having cerebrovascular disease, blood pressure should be reduced gradually to avoid hypotensive episodes. Beta-blockers or calcium antagonists (especially those that reduce heart rate) may be specifically useful in patients with angina pectoris. For those who have had a myocardial infarction, non-ISA (non-intrinsic sympathomimetic activity) beta-blockers are the drugs of choice because they have been shown to reduce the risk of a subsequent event and sudden death.⁹⁶

Patients With Cardiac Failure

Control of elevated arterial pressure can improve myocardial function, prevent

Beta-blockers or calcium antagonists may be specifically useful in patients with angina pectoris.

Effective control of pressure and other atherogenic factors may help retard or even reverse the stiffening of arteries.

Controlling high blood pressure clearly preserves renal function.

- ♦ cardiac failure, and reduce mortality. ACE inhibitors, when used alone or in combination with digitalis or diuretics in patients
- ♦ with congestive failure, are effective in reducing mortality due to progressive congestive heart failure.⁹⁷ The use of ACE inhibitors may decrease mortality even more than other vasodilator therapy.⁹⁸

♦ Patients With Left Ventricular Hypertrophy

- ♦ Left ventricular hypertrophy (LVH) permits cardiac adaptation to the increased afterload imposed by elevated blood pressure. However, LVH represents a major independent risk factor for cardiac death, myocardial infarction, and other morbid events,⁹⁹ and control of elevated blood pressure should prevent LVH.
- ♦ Echocardiography is the most sensitive and specific way to diagnose LVH, but its use is limited by cost.¹⁰⁰ The electrocardiogram remains of value not only
- ♦ for detecting LVH but also for identifying evidence of myocardial ischemia or cardiac dysrhythmias.
- ♦ All major drug classes, with the exception of direct-acting vasodilators, may reduce left ventricular mass and wall thickness,¹⁰¹
- ♦ as may weight loss,¹⁰² and decrease of dietary salt intake.¹⁰³ It is not known whether reversal of hypertension-induced cardiac hypertrophy improves the independent risk of cardiovascular morbidity and mortality associated with LVH. However, the presence of LVH is an indication for effective blood pressure control.

♦ Patients With Peripheral Vascular Diseases

- ♦ Hypertension is a major risk factor for the development of carotid atherosclerosis, arteriosclerosis obliterans, intermittent claudication, and aneurysms, including
- ♦ dissecting aneurysms; however, it is not known whether antihypertensive therapy

will alter the course of the diseases. Arterial hypertrophy and atherosclerosis may further increase SBP and the pulse pressure. Effective control of pressure and other atherogenic factors may help retard or even reverse the stiffening of arteries.

PATIENTS WITH HYPERTENSION AND OTHER COEXISTING DISEASES

Patients With Renal Disease

The hypertension of chronic renal failure is largely volume dependent due to retention of sodium and water. Thus, relatively large doses of diuretics are often needed as part of the treatment regimen. A loop diuretic (furosemide, bumetanide, ethacrynic acid) or metolazone or indapamide is usually necessary to accomplish a significant diuresis when the serum creatinine level has reached 221 $\mu\text{mol/L}$ (2.5 mg/dL) or more. Potassium supplements and potassium-sparing diuretics are relatively contraindicated in the presence of even mild renal insufficiency.

All of the commonly used classes of antihypertensive drugs are usually effective in lowering blood pressure in patients with renal disease. In those whose hypertension has become resistant to multiple drug therapy that includes large doses of loop diuretics, minoxidil may be needed. In animal experiments as well as short-term clinical trials of small subsets of selected patients with diabetic nephropathy, ACE inhibitors have been shown to reduce proteinuria and slow progression of renal disease.¹⁰⁴ However, acute renal failure can be precipitated by ACE inhibitors in hypertensive patients with bilateral renal artery stenosis, renal artery stenosis to a solitary kidney, and preexisting renal disease. Hyperkalemia is a definite risk in azotemic patients receiving ACE inhibi-

tors, especially those who have diabetic renal disease or those using nonsteroidal anti-inflammatory drugs. Therefore, serum creatinine and potassium levels should be monitored carefully before and after initiation of ACE inhibitors in patients who have renal insufficiency.

Controlling high blood pressure clearly preserves renal function. Aggressive control of hypertension also prevents or slows the progression of renal failure. It is unclear whether any antihypertensive agent is preferred in this regard. It has been suggested that blood pressure should be reduced to 130/85 mm Hg or less to provide adequate protection of renal function in hypertensive patients.¹⁰⁵

Dietary protein and phosphate restriction are appropriate nondrug therapies that may preserve renal function and should be implemented early in the course of renal insufficiency. In the advanced stages of renal insufficiency, hypertension often becomes relatively resistant to multiple drug therapy, and adequate control requires either chronic dialysis or renal transplantation.

Patients With Diabetes Mellitus

Patients with hypertension and diabetes mellitus are especially vulnerable to cardiovascular complications; therefore, the control of hypertension and dyslipidemia as well as cessation of cigarette smoking are particularly important. For these patients the blood pressure goal should be 130/85 mm Hg or less. Lifestyle modifications are beneficial for control of hyperglycemia, dyslipidemia, and hypertension, which often coexist in obese patients with insulin resistance.^{106, 107}

No antihypertensive agent is specifically contraindicated for use in the diabetic popu-

lation, but caution is needed with most drugs. Diuretic-induced hypokalemia may worsen glucose tolerance; beta-blockers may worsen glucose tolerance, mask the symptoms of and prolong recovery from hypoglycemia; α_1 -receptor blockers may aggravate postural hypotension; ACE inhibitors may induce hyperkalemia.

The potentially beneficial effect of ACE inhibitors on proteinuria and renal function in patients with diabetic renal disease is discussed in the previous section.

The syndrome of insulin resistance very closely parallels Type II diabetes mellitus. Hypertension, dyslipidemia, hyperinsulinemia, glucose intolerance, and, frequently, upper body obesity comprise this syndrome. Insulin resistance can be improved by weight loss and exercise. Short-term studies in small numbers of patients have shown that α_1 -receptor blockers and ACE inhibitors decrease insulin resistance.

Patients With Dyslipidemia

The common coexistence of hypercholesterolemia and hypertension mandates effective management of both conditions.³⁰ Since lifestyle modifications are the first approach to treatment of both conditions, great emphasis must be placed on control of overweight, reduction of cholesterol and saturated fat intake, and increased physical activity in patients with elevated lipids and hypertension.

If lifestyle modifications are not successful in controlling blood pressure, drug therapy must be added. Thiazide and loop diuretics can induce at least short-term small increases in levels of total plasma cholesterol, triglycerides, and low-density lipoprotein cholesterol. Several studies have suggested that this dyslipidemic effect may decrease or disappear with long-term

No
antihypertensive
agent is
specifically
contraindicated
for use in the
diabetic
population, but
caution is needed
with most drugs.

- ♦ therapy. Dietary modifications may reduce or eliminate these effects.

- ♦ Beta-blockers may increase levels of plasma triglycerides and reduce those of high-density lipoprotein cholesterol. Despite this effect, non-ISA beta-blockers are the only agents that have been shown to decrease, in those with previous myocardial infarction, the rate of sudden death, overall mortality, and recurrent myocardial infarction.¹⁰⁸ Beta-blockers with intrinsic sympathomimetic activity or labetalol have little or no adverse effect on lipids, but these agents have not been demonstrated to have a cardioprotective effect after a myocardial infarction.

- ♦ The α_1 -receptor blockers and the central adrenergic agonists may decrease serum cholesterol concentration to a slight degree, especially in the low-density lipoprotein subfraction. Therefore, these agents may offer an advantage in managing hypertensive patients with dyslipidemia.
- ♦ ACE inhibitors and calcium antagonists have no adverse effects on levels of serum lipids and lipoprotein.

♦ **Patients With Chronic Airways Disease or Bronchial Asthma**

- ♦ In hypertensive patients with chronic obstructive pulmonary disease (COPD)—including chronic bronchitis, emphysema, and/or asthma—beta-adrenergic blocking drugs can worsen bronchoconstriction and are therefore relatively contraindicated. Calcium antagonists do not cause bronchial constriction but in rare cases can cause or aggravate hypoxemia by dilating the pulmonary arterial circulation, thereby worsening the mismatch between regional ventilation and regional perfusion. ACE inhibitors can cause cough, which may be more significant when it complicates COPD. Recognizing these limitations, all antihypertensive agents, except beta-blockers and the alpha-beta blocker, can be used in hypertensive patients who have COPD.

nizing these limitations, all antihypertensive agents, except beta-blockers and the alpha-beta blocker, can be used in hypertensive patients who have COPD.

Methylxanthines (theophylline) and corticosteroids often used in managing COPD can worsen hypertension; in addition, methylxanthines cause tachycardia and are arrhythmogenic. Beta-adrenergic agonists used to treat COPD are not as likely as methylxanthines to worsen hypertension, but they do cause tachycardia and can be arrhythmogenic.

Over-the-counter asthma preparations may contain ephedrine as a bronchodilator, and over-the-counter common cold preparations frequently contain phenylpropanolamine or pseudoephedrine as a vasoconstrictor, all of which can increase blood pressure and heart rate.

Patients With Gout

Hyperuricemia is a frequent finding, even in untreated patients with hypertension, and may reflect a decrease in renal blood flow. In addition, all of the commonly used diuretics, including the potassium-sparing class, can increase serum uric acid and induce acute gout. Body mass and serum uric acid are closely correlated; weight loss can produce a fall in serum uric acid in overweight hypertensive patients even with diuretic treatment. For patients with poorly controlled gout, diuretics should be avoided (or used intermittently). Diuretic-induced hyperuricemia does not require treatment in the absence of gout or urate stones.

PATIENTS UNDERGOING SURGERY

Surgical candidates who are adequately controlling their blood pressure with medication should be maintained on their

regimen until the time of surgery, and therapy should be reinstated as soon as possible after surgery. If oral intake must be interrupted, parenteral therapy with diuretics, adrenergic inhibitors, vasodilators, ACE inhibitors, calcium antagonists, or transdermal clonidine may be used to prevent the rebound hypertension that may follow sudden discontinuation of some of the adrenergic-inhibiting agents.

Adequate potassium supplementation should be provided to correct hypokalemia well in advance of surgery. A brief course of intravenous potassium just prior to surgery may not be sufficient to correct longstanding hypokalemia. In all cases, anesthesiologists must be aware of the patient's medication status. Patients with hypertension whose blood pressure has been controlled on medication usually tolerate anesthesia better than do those whose pressures are poorly controlled.¹⁰⁹

MISCELLANEOUS CAUSES FOR INCREASED BLOOD PRESSURE

Cocaine

Cocaine, like the amphetamines, increases release of norepinephrine and prevents neuronal re-uptake of norepinephrine. As a result, it induces acute hypertension, tachycardia, tremor, and seizures¹¹⁰ and produces coronary artery vasoconstriction. Cocaine is also associated with ischemic and hemorrhagic cerebrovascular strokes in young adults.¹¹¹⁻¹¹³ The onset of symptoms, especially severe headache, often occurs within 1 hour of using the drug. The treatment of choice is alpha-adrenergic inhibition (e.g., phentolamine). A beta-blocker should be used for complicating cardiac dysrhythmias induced by the catecholamine excess.

Lithotripsy

Extracorporeal shock wave lithotripsy (ESWL) can cause localized vascular injury that may be associated with transient decreases in renal blood flow and glomerular filtration rate in the treated kidney, transient proteinuria, and slight elevation of diastolic blood pressure. Acute hypertension following ESWL has been reported but is exceedingly uncommon. The procedure can also cause subcapsular and perirenal hematomas and fluid collection, with the incidence of bleeding higher in patients with hypertension. There is little or no evidence, however, that these complications of ESWL lead to permanent renal damage or hypertension, but there is some concern that they may lead to capsular and perirenal scarring. There are no data to suggest specifically that patients with existing hypertension are made worse by the procedure.¹¹⁴

Cyclosporine

Cyclosporine causes vasoconstriction mediated in part by stimulation of the sympathetic nervous system and imbalance in the production of eicosanoids such as prostacyclin and thromboxane.¹¹⁵ Vasoconstriction of the afferent arteriole leads to reduction in renal blood flow and glomerular filtration rate, resulting in increased reabsorption of sodium, water, and urea.¹¹⁶ Cyclosporine also has direct nephrotoxicity manifested histologically by nephrosclerosis and interstitial fibrosis. Acute nephrotoxicity usually reverses promptly with intravenous fluids and temporary discontinuation or reduction in the dose of cyclosporine.

The vasoconstrictive and salt-retaining properties of cyclosporine lead to hypertension in 50 to 70 percent of transplant

- ♦ recipients receiving the drug and in 20
- ♦ percent of patients receiving the drug for
- ♦ other reasons. Diuretics are an effective
- ♦ therapy, but they exaggerate prerenal
- ♦ azotemia and may precipitate gout. Cal-
- ♦ cium antagonists and labetalol are effec-
- ♦ tive, as are central alpha-agonists such as
- ♦ clonidine. Diltiazem, nicardipine, and
- ♦ verapamil should be used with caution as
- ♦ they increase cyclosporine blood levels,
- ♦ but they may be given if the interaction
- ♦ is appreciated.

♦ Erythropoietin

- ♦ Recombinant human erythropoietin
- ♦ (rHuEPO) increases blood pressure in one-
- ♦ third of patients with end-stage renal dis-
- ♦ ease. In most cases this necessitates
- ♦ initiation or increase of antihypertensive
- ♦ therapy. The mechanism of hypertension
- ♦ related to rHuEPO remains uncertain. It
- ♦ is not related to the dose of rHuEPO or to
- ♦ the final hematocrit level achieved or to
- ♦ the rate of increase of hematocrit. It is
- ♦ associated with an increase in systemic
- ♦ vascular resistance due largely to an in-
- ♦ crease in blood viscosity and reversal of
- ♦ hypoxic vasodilatation. Acute elevation
- ♦ in blood pressure during therapy with
- ♦ rHuEPO occasionally results in hyper-
- ♦ tensives encephalopathy and seizures. Fre-
- ♦ quent blood pressure monitoring during
- ♦ the first 4 months of treatment is manda-
- ♦ tory. If conventional antihypertensive
- ♦ therapy does not control hypertension,
- ♦ the dose of rHuEPO should be reduced
- ♦ or therapy temporarily discontinued.¹¹⁷

♦

♦

♦

♦

♦

REFERENCES

1. Roberts J. Blood pressure of persons 18-74 years, United States, 1971-72. Data from the National Health Survey, Washington, DC: National Center for Health Statistics, 1975; DHEW publication no. 75-1632. (Vital and health statistics; series 11, no. 150).
2. Rowland M, Roberts J. Blood pressure levels and hypertension in persons ages 6-74 years: United States, 1976-80. Hyattsville, Md: National Center for Health Statistics, October 1982; DHHS publication no. 82-1250. (Advance data from vital and health statistics; no. 84).
3. Roccella EJ, Lenfant C. Regional and racial differences among stroke victims in the United States. *Clin Cardiol.* 1989;12:IV-18-IV-22.
4. Trials of Hypertension Prevention Collaborative Research Group. The effects of nonpharmacologic interventions of blood pressure of persons with high normal levels: results of the Trials of Hypertension Prevention, Phase I. *JAMA.* 1992;267:1213-1220.
5. Stamler R, Stamler J, Gosch FC, et al. Primary prevention of hypertension by nutritional-hygienic means: final report of a randomized, controlled trial. *JAMA.* 1989;262:1801-1807.
6. Frohlich ED, Grim C, Labarthe DR, et al. Recommendations for human blood pressure determination by sphygmomanometers. Report of a special task force appointed by the Steering Committee, American Heart Association. *Hypertension.* 1988;11:209A-222A.
7. American Society of Hypertension. Recommendations for routine blood pressure measurement by indirect cuff sphygmomanometry. *Am J Hypertens.* 1992;5:207-209.
8. Working Group on Ambulatory Blood Pressure Monitoring, National High Blood Pressure Education Program Coordinating Committee. National High Blood Pressure Education Program working group report on ambulatory blood pressure monitoring. *Arch Intern Med.* 1990;150:2270-2280.
9. Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G. Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. *J Hypertens.* 1987;5:93-98.
10. Perloff D, Sokolow M, Cowan RM, Juster RP. Prognostic value of ambulatory blood pressure measurements: further analyses. *J Hypertens.* 1989;7(Suppl 3):S3-S10.
11. Pickering TG, Devereux RB. Ambulatory monitoring of blood pressure as a predictor of cardiovascular risk. *Am Heart J.* 1987;114:925-928.
12. Gifford RW Jr, Kirkendall W, O'Connor DT, Weidman W. Office evaluation of hypertension: a statement for health professionals by a Writing Group of the Council for High Blood Pressure Research, American Heart Association. *Circulation.* 1989;79:721-731.
13. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. *Circulation.* 1991;83:356-362.
14. Levine DM, Bone L. The impact of a planned health education approach on the control of hypertension in a high risk population. *J Hum Hypertens.* 1990;4:317-321.
15. Farquhar JW, Fortmann SP, Flora JA, et al. Effects of communitywide education on cardiovascular disease risk factors: the Stanford Five-City Project. *JAMA.* 1990;264:359-365.

- ♦ 16. Lefebvre RC, Lasater TM, Carleton RA, Peterson G. Theory and delivery of health programming in the community: the Pawtucket Heart Health Program. *Prev Med.* 1987;16:80-95.
- ♦ 17. Mittelmark MB, Luepker RV, Jacobs DR, et al. Community-wide prevention of cardiovascular disease: education strategies of the Minnesota Heart Health Program. *Prev Med.* 1986;15:1-17.
- ♦ 18. National High Blood Pressure Education Program. Measuring progress in high blood pressure control: an evaluation handbook. Bethesda, Md: U.S. Department of Health and Human Services, National Heart, Lung, and Blood Institute, April 1986, NIH publication no. 86-2647.
- ♦ 19. World Hypertension League. WHL workshop: economics of hypertension control. *World Hypertens News.* December 1991, no. 20, p.4.
- ♦ 20. Task Force on the Availability of Cardiovascular Drugs to the Medically Indigent. Report of the Task Force on the Availability of Cardiovascular Drugs to the Medically Indigent. *Circulation.* 1992;85:850-860.
- ♦ 21. Pickering TG. The potential contribution of ambulatory blood pressure monitoring to decision making in hypertension and its impact on the health-care system. In: Pickering TG, Pieper C, Schechter CB, eds. *Ambulatory monitoring and blood pressure variability.* London: Science Press; 1991:15.1-15.8.
- ♦ 22. Floras JS. Will knowing the variability of ambulatory blood pressure improve clinical outcome? An additional consideration in the critical evaluation of this technology. *Clin Invest Med.* 1991;14:231-240.
- ♦ 23. Fletcher AE, Bulpitt CJ. How far should blood pressure be lowered? *N Engl J Med.* 1992;326:251-254.
- ♦ 24. Treatment of Mild Hypertension Research Group. The Treatment of Mild Hypertension Study: a randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. *Arch Intern Med.* 1991;151:1413-1423.
- ♦ 25. Wassertheil-Smoller S, Blaufox MD, Oberman AS, Langford HG, Davis BR, Wylie-Rosett J. The Trial of Antihypertensive Interventions and Management (TAIM) study: adequate weight loss, alone and combined with drug therapy in the treatment of mild hypertension. *Arch Intern Med.* 1992;152:131-136.
- ♦ 26. Hypertension Prevention Trial Research Group. The Hypertension Prevention Trial: three-year effects of dietary changes on blood pressure. *Arch Intern Med.* 1990;150:153-162.
- ♦ 27. Subcommittee on Nonpharmacologic Therapy of the 1984 Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Nonpharmacological approaches to the control of high blood pressure. *Hypertension.* 1986;8:444-467.
- ♦ 28. Stamler R, Stamler J, Grimm R, et al. Nutritional therapy for high blood pressure: final report of a four-year randomized controlled trial—the Hypertension Control Program. *JAMA.* 1987;257:1484-1491.
- ♦ 29. Little P, Girling G, Hasler A, Trafford A. A controlled trial of a low sodium, low fat, high fibre diet in treated hypertensive patients: effect on antihypertensive drug requirement in clinical practice. *J Hum Hypertens.* 1991;5:175-181.
- ♦ 30. Working Group on Management of Patients with Hypertension and High Blood Cholesterol. National Education Programs working group report on the management of patients with hypertension and high blood cholesterol. *Ann Intern Med.* 1991;114:224-237.
- ♦ 31. Greenberg G, Thompson SG, Brennan PJ. The relationship between smoking and the response to antihypertensive treatment in mild hypertensives in the Medical Research Council's Trial of Treatment. *Int J Epidemiol.* 1987;16:25-30.
- ♦ 32. Langford HG, Stamler J, Wassertheil-Smoller S, Prineas RJ. All-cause mortality in the Hypertension Detection and Follow-up Program: findings in the whole cohort and for persons with less severe hypertension, with and without other traits related to risk of mortality. *Prog Cardiovasc Dis.* 1986;29(Suppl 1):29-54.
- ♦ 33. Després J-P, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. *Arteriosclerosis.* 1990;10:497-511.

34. Langford HG, Davis BR, Blaufox MD, et al. Effect of drug and diet treatment of mild hypertension on diastolic blood pressure. *Hypertension*. 1991;17:210-217.
35. Schotte DE, Stunkard AJ. The effects of weight reduction on blood pressure in 301 obese patients. *Arch Intern Med*. 1990;150:1701-1704.
36. World Hypertension League. Alcohol and hypertension—implications for management: a consensus statement by the World Hypertension League. *J Hum Hypertens*. 1991;5:1854-1856.
37. Maheswaran R, Gill JS, Davies P, Beevers DG. High blood pressure due to alcohol: a rapidly reversible effect. *Hypertension*. 1991;17:787-792.
38. Blair SN, Kohl HW III, Paffenbarger RS Jr, Clark DG, Cooper KH, Gibbons LW. Physical fitness and all-cause mortality: a prospective study of healthy men and women. *JAMA*. 1989;262:2395-2401.
39. Blair SN, Goodyear NN, Gibbons LW, Cooper KH. Physical fitness and incidence of hypertension in healthy normotensive men and women. *JAMA*. 1984;252:487-490.
40. World Hypertension League. Physical exercise in the management of hypertension: a consensus statement by the World Hypertension League. *J Hypertens*. 1991;9:283-287.
41. Intersalt Cooperative Research Group. Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. *Br Med J*. 1988;297:319-328.
42. Law MR, Frost CD, Wald NJ. By how much does dietary salt reduction lower blood pressure? I—Analysis of observational data among populations. *Br Med J*. 1991;302:811-815.
43. Intersalt Cooperative Research Group. Sodium, potassium, body mass, alcohol and blood pressure: the INTERSALT Study. *J Hypertens*. 1988;6(Suppl 4):S584-S586.
44. Cutler JA, Follmann D, Elliott P, Suh I. An overview of randomized trials of sodium reduction and blood pressure. *Hypertension*. 1991;17(Suppl I):I-27-I-33.
45. Law MR, Frost CD, Wald NJ. By how much does dietary salt reduction lower blood pressure? III—Analysis of data from trials of salt reduction. *Br Med J*. 1991;302:819-824.
46. Sullivan J. Salt sensitivity: definition, conception, methodology, and long-term issues. *Hypertension*. 1991;17(Suppl I):I-61-I-68.
47. Flack JM, Ensrud KE, Mascioli S, et al. Racial and ethnic modifiers of the salt-blood pressure response. *Hypertension*. 1991;17(Suppl I):I-115-I-121.
48. Grobbee DE. Methodology of sodium sensitivity assessment: the example of age and sex. *Hypertension*. 1991;17(Suppl I):I-109-I-114.
49. Linas SL. The role of potassium in the pathogenesis and treatment of hypertension. *Kidney Int*. 1991;39:771-786.
50. Hamet P, Mongeau E, Lambert J, et al. Interactions among calcium, sodium, and alcohol intake as determinants of blood pressure. *Hypertension*. 1991;17(Suppl I):I-150-I-154.
51. Cutler JA, Brittain E. Calcium and blood pressure: an epidemiologic perspective. *Am J Hypertens*. 1990;3:137S-146S.
52. Sacks FM. Dietary fats and blood pressure: a critical review of the evidence. *Nutr Rev*. 1989;47:291-300.
53. Knapp HR, Fitzgerald GA. The antihypertensive effects of fish oil: a controlled study of polyunsaturated fatty acid supplements in essential hypertension. *N Engl J Med*. 1989;320:1037-1043.
54. van Montfrans GA, Karemaker JM, Wieling W, Dunning AJ. Relaxation therapy and continuous ambulatory blood pressure in mild hypertension: a controlled study. *Br Med J*. 1990;300:1368-1372.
55. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. *Lancet*. 1990;335:827-838.
56. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. *Lancet*. 1990;335:765-774.
57. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. *JAMA*. 1991;265:3255-3264.

- ♦ 58. Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekblom T, Wester P-O. Morbidity and mortality in the Swedish Trial in Old Patients With Hypertension (STOP-Hypertension). *Lancet*. 1991;338:1281-1285.
- ♦ 59. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. *Br Med J*. 1992;304:405-412.
- ♦ 60. Hypertension Detection and Follow-up Program Cooperative Group. The effect of treatment on mortality in "mild" hypertension: results of the Hypertension Detection and Follow-up Program. *N Engl J Med*. 1982;307:976-980.
- ♦ 61. Alderman MH. Which antihypertensive drugs first—and why! *JAMA*. 1992;267:2786-2787.
- ♦ 62. Olin BR, ed. Drug facts and comparisons. St. Louis, Mo: JB Lippincott;1991:495-806.
- ♦ 63. Lam YWF, Shepherd MM. Drug interactions in hypertensive patients: pharmacokinetic, pharmacodynamic and genetic considerations. *Clin Pharmacokinet*. 1990;18:295-317.
- ♦ 64. Hansten PD, Horn JR. Drug interactions and updates. Malvern, Penn: Lea & Febiger;1990.
- ♦ 65. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. *Arch Intern Med*. 1990;150:1881-1884.
- ♦ 66. Farnett L, Mulrow CD, Linn WD, Lucey CR, Tuley MR. The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? *JAMA*. 1991;265:489-495.
- ♦ 67. Gifford RW Jr. Management of hypertensive crises. *JAMA*. 1991;266:829-835.
- ♦ 68. Working Group on Health Education and High Blood Pressure Control, National High Blood Pressure Education Program. The physician's guide: improving adherence among hypertensive patients. Bethesda, Md: U.S. Department of Health and Human Services, National Heart, Lung, and Blood Institute, March 1987.
- ♦ 69. Tyroler HA. Twenty-year mortality in black residents of Evans County, Georgia. *J Clin Hypertens*. 1987;3(Suppl):9S-15S.
70. Gillum RF. Cardiovascular disease in the United States: an epidemiologic overview. In: Saunders E, ed. Cardiovascular diseases in blacks. Philadelphia, Penn: FA Davis;1991:3-16.
71. Ferguson R, Grim CE, Opgenorth TJ. The epidemiology of end-stage renal disease: the six-year South-Central Los Angeles experience, 1980-85. *Am J Public Health*. 1987;77:864-865.
72. Ooi WL, Budner NS, Cohen H, et al. Impact of race on treatment response and cardiovascular disease among hypertensives. *Hypertension*. 1989;14:227-234.
73. Task Force on Blood Pressure Control in Children. Report of the Second Task Force on Blood Pressure Control in Children—1987. *Pediatrics*. 1987;79:1-25.
74. MacMahon SW, Furberg CD, Cutler JA. Women as participants in trials of the primary and secondary prevention of cardiovascular disease: part I. Primary prevention: the hyper-tension trials. In: Eaker ED, Packard B, Wenger NK, Clarkson TB, Tyroler HA, eds. Coronary heart disease in women. Proceedings of an N.I.H. workshop. New York, NY: Haymarket Doyma;1987:233-240.
75. Anastos K, Charney P, Charon RA, et al. Hypertension in women: what is really known? *Ann Intern Med*. 1991;115:287-293.
76. Woods JW. Oral contraceptives and hypertension. *Hypertension*. 1988;11(Suppl II):II-11-II-15.
77. Layde PM, Beral V, Kay CR. Further analyses of mortality in oral contraceptive users. Royal College of General Practitioners' Oral Contraception Study. *Lancet*. 1981;1:541-546.
78. Lim KG, Isles CG, Hodsman GP, Lever AF, Robertson JWK. Malignant hypertension in women of childbearing age and its relation to the contraceptive pill. *Br Med J*. 1987;294:1057-1059.
79. National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Working Group Report on High Blood Pressure in Pregnancy. *Am J Obstet Gynecol*. 1990;163:1689-1712.
80. Hanssens M, Keirse MJNC, Vankelecom F, Van Assche FA. Fetal and neonatal effects of treatment with angiotensin-converting-enzyme inhibitors in pregnancy. *Obstet Gynecol*. 1991;78:128-135.

81. Barron WM. Hypertension. In: Barron WM, Lindheimer MD, eds. *Medical disorders in pregnancy*. Chicago, Ill: Mosby-Year Book;1991:1-42.
82. Butters L, Kennedy S, Rubin PC. Atenolol in essential hypertension during pregnancy. *Br Med J*. 1990;301:587-589.
83. Pritchard JA, Cunningham FG, Pritchard FA. The Parkland Memorial Hospital protocol for treatment of eclampsia: Evaluation of 245 cases. *Am J Obstet Gynecol*. 1984;148:951-963.
84. Collins R, Wallenburg HCS. Pharmacologic prevention and treatment of hypertensive disorders in pregnancy. In: Chalmers I, Enkin M, Keirse MJNC, eds. *Effective care in pregnancy and childbirth. Volume 1: Pregnancy*. Oxford, England: Oxford University Press;1989:512-533.
85. Wren BG, Routledge DA. Blood pressure changes: oestrogens in climacteric women. *Med J Aust*. 1981;2:528-531.
86. Messerli FH. Osler's maneuver, pseudohypertension, and true hypertension in the elderly. *Am J Med*. 1986;80:906-910.
87. Management Committee. Treatment of mild hypertension in the elderly. *Med J Aust*. 1981;2:398-402.
88. Amery A, Birkenhäger W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. *Lancet*. 1985;1:1349-1354.
89. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. *Br Med J*. 1986;293:1145-1151.
90. Stamler J. Risk factor modification trials: implications for the elderly. *Eur Heart J*. 1988;9(Suppl D):9-53.
91. Brott T, Reed RL. Intensive care for acute stroke in the community hospital setting: the first 24 hours. *Stroke*. 1989;20:577-582.
92. Phillips SJ, Whisnant JP, on behalf of the National High Blood Pressure Education Program. Hypertension and the brain. *Arch Intern Med*. 1992;152:938-945.
93. Multiple Risk Factor Intervention Trial Research Group. Exercise electrocardiogram and coronary heart disease mortality in the Multiple Risk Factor Intervention Trial. *Am J Cardiol*. 1985;55:16-24.
94. Multiple Risk Factor Intervention Trial Research Group. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial: findings related to a priori hypotheses of the trial. *JAMA*. 1990;263:1795-1801.
95. Rautaharju PM, Neaton JD. Electrocardiographic abnormalities and coronary heart disease mortality among hypertensive men in the Multiple Risk Factor Intervention Trial. *Clin Invest Med*. 1987;10:606-615.
96. Yusuf S, Wittes J, Probstfield J. Evaluating effects of treatment in subgroups of patients within a clinical trial: the case of non-Q-wave myocardial infarction and beta blockers. *Am J Cardiol*. 1990;66:220-222.
97. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. *N Engl J Med*. 1991;325:293-302.
98. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. *N Engl J Med*. 1991;325:303-310.
99. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. *N Engl J Med*. 1990;322:1561-1566.
100. Devereux RB, Casale PN, Wallerson DC, et al. Cost-effectiveness of echocardiography and electrocardiography for detection of left ventricular hypertrophy in patients with systemic hypertension. *Hypertension*. 1987;9(Suppl 2):69-76.
101. Frohlich ED, Apstein C, Chobanian AV, et al. The heart in hypertension. *N Engl J Med*. 1992;327:998-1008.
102. MacMahon SW, Wilcken DEL, MacDonald GJ. The effect of weight reduction on left ventricular mass. *N Engl J Med*. 1986;314:334-339.
103. Ferrara LA, de Simone G, Pasanisi F, Mancini M, Mancini M. Left ventricular mass reduction during salt depletion in arterial hypertension. *Hypertension*. 1984;6:755-759.
104. Mogensen CE. Angiotensin converting enzyme inhibitors and diabetic nephropathy: their effects on proteinuria may be independent of their effects on blood pressure. *Br Med J*. 1992;304:327-328.

- ✦

◀

✦

•

6

1

GLOSSARY

		MRC	Medical Research Council	♦
		MRFIT	Multiple Risk Factor Intervention Trial	♦
		NCHS	National Center for Health Statistics	♦
		NHANES	National Health and Nutrition Examination Survey	♦
		NHBPEP	National High Blood Pressure Education Program	♦
		NHLBI	National Heart, Lung, and Blood Institute	♦
		NSAID's	nonsteroidal anti-inflammatory drugs	♦
		rHuEPO	recombinant human erythropoietin	♦
		SBP	systolic blood pressure	♦
		SHEP	Systolic Hypertension in the Elderly Program	♦
ABPM	ambulatory blood pressure monitoring	SOLVD	Studies of Left Ventricular Dysfunction	♦
ACE	angiotensin converting enzyme	STOP-Hypertension	Swedish Trial in Old Patients With Hypertension	♦
CHD	coronary heart disease	TAIM	Trial of Antihypertensive Interventions and Management	♦
COPD	chronic obstructive pulmonary disease	TOD	target-organ disease	♦
CVD	cardiovascular disease	TOHP	Trials of Hypertension Prevention	♦
DBP	diastolic blood pressure	TOMHS	Treatment of Mild Hypertension Study	♦
ESWL	extracorporeal shock wave lithotripsy			♦
EWPH	European Working Party on High Blood Pressure in the Elderly			♦
HDFP	Hypertension Detection and Follow-up Program			♦
HPT	Hypertension Prevention Trial			♦
ISA	intrinsic sympathomimetic activity			♦
ISH	isolated systolic hypertension			♦
LVH	left ventricular hypertrophy			♦
mg/dL	milligrams per deciliter			♦
mm Hg	millimeters of mercury			♦

CLASSIFICATION OF BLOOD PRESSURE FOR ADULTS AGE 18 YEARS AND OLDER*

Average DBP mm Hg	Average SBP mm Hg		
	< 120	120-129	130-139
< 80	Optimal†	Normal	High Normal
80-84	Normal	Normal	High Normal
85-89	High Normal	High Normal	High Normal
≥ 90	High	High	High

† Optimal blood pressure, with regard to cardiovascular risk, is SBP <120 mm Hg and DBP <80 mm Hg. However, unusually low readings should be evaluated for clinical significance.

* Not taking antihypertensive drugs and not acutely ill. When systolic and diastolic pressure fall into different categories, the higher category should be selected to classify the individual's blood pressure status. For instance, 160/92 should be classified as Stage 2, and 180/120 should be classified as Stage 4. Isolated systolic hypertension (ISH) is defined as SBP ≥140 mmHg and DBP <90 mm Hg and staged appropriately (e.g., 170/85 mm Hg is defined as Stage 2 ISH).

Category	Systolic mm Hg	Diastolic mm Hg
Normal	< 130	< 85
High normal	130-139	85-89
Hypertension**		
STAGE 1 (Mild)	140-159	90-99
STAGE 2 (Moderate)	160-179	100-109
STAGE 3 (Severe)	180-209	110-119
STAGE 4 (Very Severe)	≥ 210	≥ 120

** Based on the average of two or more readings taken at each of two or more visits following an initial screening.

Note: In addition to classifying stages of hypertension based on average blood pressure levels, the clinician should specify presence or absence of target-organ disease and additional risk factors. For example, a patient with diabetes and a blood pressure of 142/94 mm Hg plus left ventricular hypertrophy should be classified as "Stage 1 hypertension with target-organ disease (left ventricular hypertrophy) and with another major risk factor (diabetes)." This specificity is important for risk classification and management.

CLASSIFICATION OF STAGES OF HIGH BLOOD PRESSURE FOR ADULTS
AGE 18 YEARS OR OLDER*

Average DBP mm Hg	Average SBP mm Hg				
	< 140	140-159	160-179	180-209	≥210
< 90	No HBP	1	2	3	4
90-99	1	1	2	3	4
100-109	2	2	2	3	4
110-119	3	3	3	3	4
≥ 120	4	4	4	4	4

* Not taking antihypertensive drugs and not acutely ill. When systolic and diastolic pressure fall into different categories, the higher category should be selected to classify the individual's blood pressure status. For instance, 160/92 should be classified as Stage 2, and 180/120 should be classified as Stage 4. Isolated systolic hypertension (ISH) is defined as SBP ≥140 mm Hg and DBP <90 mm Hg and staged appropriately (e.g., 170/85 mm Hg is defined as Stage 2 ISH).

Note: In addition to classifying stages of hypertension based on average blood pressure levels, the clinician should specify presence or absence of target-organ disease and additional risk factors. For example, a patient with diabetes and a blood pressure of 142/94 mm Hg plus left ventricular hypertrophy should be classified as "Stage 1 hypertension with target-organ disease (left ventricular hypertrophy) and with another major risk factor (diabetes)." This specificity is important for risk classification and management.

RECOMMENDATIONS FOR FOLLOWUP BASED ON INITIAL SET OF
BLOOD PRESSURE MEASUREMENTS FOR ADULTS AGE 18 AND OLDER

Initial Screening Blood Pressure (mm Hg) [†]		Followup Recommended**
Systolic	Diastolic	
< 130	< 85	Recheck in 2 years
130-139	85-89	Recheck in 1 year [§]
140-159	90-99	Confirm within 2 months
160-179	100-109	Evaluate or refer to source of care within 1 month
180-209	110-119	Evaluate or refer to source of care within 1 week
≥ 210	≥ 120	Evaluate or refer to source of care immediately

[†] If the systolic and diastolic categories are different, follow recommendation for the shorter time followup (e.g., 160/85 mm Hg should be evaluated or referred to source of care within 1 month).

^{**} The scheduling of followup should be modified by reliable information about past blood pressure measurements, other cardiovascular risk factors, or target-organ disease.

[§] Consider providing advice about lifestyle modifications (see Chapter III).

DISCRIMINATION PROHIBITED: Under provisions of public laws enacted by Congress since 1964, no person in the United States shall, on the grounds of race, color, national origin, handicap, or age, be excluded from participation in, be denied the benefits of, or be subjected to discrimination under any program or activity (or, on the basis of sex, with respect to any education program or activity) receiving Federal financial assistance. In addition, Executive Order 11141 prohibits discrimination on the basis of age by contractors and subcontractors in the performance of Federal contracts, and Executive Order 11246 states that no federally funded contractor may discriminate against any employee or applicant for employment because of race, color, religion, sex, or national origin. Therefore, the *NATIONAL HEART, LUNG, AND BLOOD INSTITUTE* must be operated in compliance with these laws and Executive Orders.



<http://nihlibrary.nih.gov>

10 Center Drive
Bethesda, MD 20892-1150
301-496-1080



50% recycled fiber
10% postconsumer fiber



3 1496 00585 1285

Department of Health and Human Services
Public Health Service
National Institutes of Health, Bldg. 31, Room 4A05
Bethesda, Maryland 20892

[Publication No. 93-1088

January 1993

Official Business

Penalty for private use, \$300

~~12/17/99~~
~~11:5343838~~

~~OCT 28 1994~~

~~NOV 8 1994~~

~~DEC 12 1994~~

~~JAN 10 1995~~

~~SEP 21 1995~~

~~JAN 13 1997~~

~~AUG 10 1998~~

First Class Mail
Postage & Fees Paid
DHHS/NIH
Permit No. G-763